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Melastoma malabathricum L. (Melastomataceae) is one of the 22 species found in the Southeast Asian region, including Malaysia.
Considered as native to tropical and temperate Asia and the Paciﬁc Islands, this commonly found small shrub has gained herbal
status in the Malay folklore belief as well as the Indian, Chinese, and Indonesian folk medicines. Ethnopharmacologically, the
leaves, shoots, barks, seeds, and roots of M. malabathricum have been used to treat diarrhoea, dysentery, hemorrhoids, cuts and
wounds, toothache, and stomachache. Scientiﬁc ﬁndings also revealed the wide pharmacological actions of various parts of M.
malabthricum, such as antinociceptive, anti-inﬂammatory, wound healing, antidiarrheal, cytotoxic, and antioxidant activities.
Various types of phytochemical constituents have also been isolated and identifed from diﬀerent parts of M. malabathricum.T h u s ,
the aim of the present review is to present comprehensive information on ethnomedicinal uses, phytochemical constituents, and
pharmacological activities of M. malabathricum.
1.Introduction
Melastomataceae plants originate in the tropic and subtropic
regions, with a total of more than 4000 species in the world.
In the Southeast Asian region alone, the genus Melastoma
comprises22species,2subspecies,and3varieties[1].Malay-
sia, particularly, with a tropical climate, is home to at least 12
species, many of which are used by natives in folk medicine.
One of the plants within the Melastomataceae family that
have gained herbs status in the Malay folklore belief is Melas-
toma malabathricum Linn., which has been known to com-
prise two subspecies, namely, M. malabathricum L. ssp. mal-
abathricum and M. malabathricum Linn ssp. normale [2].
In general, M. malabathricum is a small shrub commonly
found in previously cleared land, waste places, and road-
side throughout the Southeast Asian countries, including
Malaysia [3]. It is native to tropical and temperate Asia and
the Paciﬁc Islands [4]. The plant is one of the most common
weeds that grow wildly and abundantly throughout the tro-
pics, especially in the moist areas, and can be found in the
Indian Ocean Islands, throughout South and South-East
Asia, China, Taiwan, Australia, and the South Paciﬁc Ocean
[5].ThroughoutMalaysia,particularly,theplantisverycom-
mon in the lowland and mountain forests, chieﬂy in open
places. M. malabathricum has diﬀerent vernacular names
depending on the location (e.g., Malaysia, Indonesia, China,
and India) where the plant was found and the communities
or tribes (e.g., Malay, Chinese, and Indian) that used them
traditionally for medicinal purposes [4, 6–20]( Table 1).2 Evidence-Based Complementary and Alternative Medicine
Table 1 :T h ev e r n a c u l a rn a m eo fM. malabthricum.
No. Vernacular names Language Country References
1 Senduduk, Sekeduduk,
Kenduduk Malay Malaysia Abdul Majid and Ting [6]
Fazlin et al. [7]
2
Kendudu, Pucuk Kenduduk Riau Grosvenor et al. [8]
Harendong Sunda Indonesia Abdul Majid and Ting [6]
Kluruk, Senggani Jawa Fazlin et al. [7]
3 Singapore rhododendron English Singapore, Britain Ling et al. [4]
Malabar melastome Britain Umali-Stuart and
Stiuart-Santiago [9]
4 Mang kre, Mang re, Bre,
Kadu-da Thais Thailand Fazlin et al. [7]
5
Malatungau, Malatungaw Ibanag
Bubtoi Sambali Philippine Umali-Stuart and
Stiuart-Santiago [9]
Yagomyum Cebu Bisaya
6 Ye mu dan Chinese China Zhengyi et al. [10]
7
Builukhampa Mizoram Sharma et al. [11]
Yachubi Manipur (Meitei tribe) Khumbongmayum et al. [12]
Longumpo, Bobuchunmei Manipur (Naga tribe) Ringmichon et al. [15]
Karali Malkangiri India Pattanaik et al. [13]
Chuthuksuru Wokha (Loga-Naga tribes) Jamir et al. [17]
Kechi-yaying Arunachal Pradesh (Adi tribes) Kagyung et al. [16]
Koroli Mayurbhanj Thatoi et al. [14]
8
Koiam-pay-bang Bandarban (Marma tribe) Rahmatullah et al. [18]
Kakkhu Netrakona (Garo tribe) Bangladesh Rahmatullah et al. [19]
Aksio Chittaggong (Chakma, Murong,
Tonchonga tribes) Rahmatullah et al. [20]
Figure 1: The shrubs of Melastoma malabathricum L. (adapted
from http://www.google.com/).
This showy bush of small trees rapidly colonises waste-
lands as their seeds are dispersed by birds. The characteris-
tics of M. malabathricum include its average height of
0.5–1(−5)m high but may occasionally grow up to 5m
long (Figure 1). The stems are 4-sided to subterete, generally
bristly, covered with small rough scales, and reddish. Bran-
chlets are numerous, procumbent, densely covered with ap-
pressed scales. The petiole is approximately 0.5–1.9cm while
the leaves are blade ovate, elliptic, or elliptic-lanceolate, 4–14
Figure 2: The leaves and fruits of M. malabathricum L. (adapted
from http://www.google.com/).
× 1.7–3.5(−6)cm, stiﬄy papery, abaxially densely strigose
and puberulous, adaxially densely strigose, secondary veins
2 (or 3) on each side of midvein, tertiary veins numerous
andparallel,baseroundedtosubcordate,marginentire,apex
acuminate (Figure 2). Inﬂorescences subcapitate corymbose,
terminal, 3–7-ﬂowered, with 2 leaﬂike bracts at base. Ped-
icel 2–8(−10)mm, strigose, apically 2-bracteolate, bracteoles
lanceolate to subulate, 2–5mm, abaxially densely strigose,
margin ciliate. Hypanthium 5–9mm, densely compressedEvidence-Based Complementary and Alternative Medicine 3
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Figure 3: Melastoma malabathricum ﬂowers with diﬀerent petal colour. (a) Dark purple-magenta petals, (b) light pink-magenta petals, and
(c) white petals (adapted from http://www.google.com/).
strigose, margin ﬁmbriate. Calyx lobes lanceolate to ovate-
lanceolate, apex acuminate, on both sides and along their
margin squamosly strigose and pubescent. Petals reddish
purple, 2-3(−4) cm, margin only ciliate, apex rounded. The
ﬂowers,whichareshort-livedandlastonlyaday,growin5to
10 clusters and have 5 petals [21]. The ﬂower has ten stamens
of two diﬀerent kinds: ﬁve larger ones with yellow ﬁlaments
and purple curved upper parts including the anther and ﬁve
smaller ones with yellow and straight ﬁlaments and yellow
anthers. On rare occasions, M. malabathricum consists
of three varieties, having large-, medium- and small-size
ﬂowers with dark purple-magenta petals (Figure 3(a)), light
pink-magenta petals (Figure 3(b)), and (the rare variety)
white petals (Figure 3(c))[ 22]. The calyx closely set with
short chaﬀy and silky or silvery scale. Longer stamens with
connective long extended at base, curved, apex biﬁd. Shorter
stamens with anthers 2-tuberculate at base; connective not
extended. Ovary half inferior, densely strigose, apically with
a ring of setae. Fruit urceolate-globular, 6–15 × 6–12mm,
succulent, densely squamose strigose [10] .T h ef r u i t sa r e
technically classiﬁed as berries, and, when they are ripe, they
break open irregularly to reveal the soft, dark purple, sweet
but rather astringent-tasting pulp and numerous orange
seeds (Figures 4(a) and 4(b)). The seeds are dimorphic: with
or without embryos. Fertile seeds are folded or spiral, tri-
angular to D-shaped in outline, 0.45–0.8mm long, 0.35–
0.6mm wide, 0.17–0.3mm thick, with light yellow or pale to
dark cream-coloured testa. Seeds without embryo are similar
to the fertile seeds but smaller, 0.3–0.5mm long, 0.2–0.3mm
wide, 0.2mm thick, appear collapsed, dented, or wrinkled
and with completely black or reddish-black testa. The seeds
are tasteless and can be eaten, and they stain the tongue
black. The name “melastoma” is Greek for “black mouth,” a
name appreciated by generations of children who have eaten
the berries. M. malabathricum has evergreens and ﬂowers
throughout the year [23].
M. malabathricum has been claimed to possess various
medicinal values according to the communities/tribes tra-
ditional beliefs and, interestingly, the whole plant could be
used as herbal medicine. It is also a well-known herb in
Malaysia, particularly, where its leaves, shoots, and roots are
prepared in various ways for treatment of diﬀerent diseases
and ailments (Table 2(a)). Many reviews have appeared in
the literature regarding M. malabathricum medicinal uses.
However, none have described the complete chemical and
pharmacological properties of this important ethnomedic-
inal plant. Therefore, we aimed to compile an up-to-date
and comprehensive review of M. malabthricum that covers
its ethnomedicinal uses, phytochemical contents, and scien-
tiﬁcally proven pharmacological properties.4 Evidence-Based Complementary and Alternative Medicine
(a) (b)
Figure 4: The fruits of Melastoma malabathricum. (a) Unripe fruits, and (b) ripe fruits revealing the soft, dark purple, sweet pulp, and
numerous orange seeds (adapted from http://www.google.com/).
2. EthnomedicinalUses
There are a lot of uses for M. malabathricum reported in
folk medicine, but not supported by clinical data [23–25].
Generally, various parts (e.g., leaf, roots, and/or barks) of
the plant are used in Malay, Indian, and Indonesian folk
medicines to treat various types of ailments and diseases, for
example, diarrhoea, dysentery, leucorrhoea, hemorrhoids,
cuts and wounds, infection during conﬁnement, toothache,
stomachache, ﬂatulence, sore legs, and thrush [23, 26, 27]
(Table 2). There is also report on the use of M. malaba-
thricum seeds in the famous “poh chi” pills to treat diarrhea
in traditional Chinese medicine [28].
2.1.ReportsonTraditionalUsesofVariousPartsofM.malaba-
thricum. The leaves are chewed up, pounded, and applied as
paste on cuts or wounds or ﬁnely chopped up and squeezed
to apply the juice onto the wound to stop bleeding [29, 30].
According to Sharma et al. [11] the leaves can also be
used to prevent scarring from smallpox, to treat dysentery,
diarrhoea, and piles, and as a tonic. The young leaves are
eaten to treat diarrhea while the young premature leaves
are consumed raw to cure dysentery [23, 31]. The shoots
can be ingested to treat puerperal infections, high blood
pressure, and diabetes [23, 24] while the shoots juice can also
be used as a mouthwash to relieve a toothache or to treat
leukorrhea. Other than those mentioned above, the leaves
are also medicinally useful to treat ulcers, gastric ulcers, scar,
pimple, and black spot at skin [32]. The roots can also
be used as mouthwash to relieve a toothache and to treat
epilepsy[24,25,32],giventopostpartumwomentoaidheal-
ing and womb strengthening [7, 25, 30]o rt oa l l e v i a t er h e u -
matism, arthritis, and tenderness in the legs [23, 24]. The
decoction of the roots is used to treat diarrhea [33]. In ad-
dition, the roots’ liquid can be applied to lessen the soreness
due to thrush in children [23, 24]. The barks are medicinally
useful for the treatment of various skin diseases [34]. The
ﬂowers are also used in India to treat cancer [35].
Otherthanthat,thepowderedleavesandrootscanbeap-
plied to wounds and pox scars to aid the healing process [7,
24]orusedtorelievethediscomfortofhemorrhoids[7]with
theformeralsousedasastringentfordysentery[9].Thejuice
ofleavesandrootsisusedasadigestiveaid[9].Furthermore,
the leaves and ﬂowers are useful for the treatment of cholera,
diarrhoea, prolonged fever, dysentery, leucorrhoea, wounds,
and skin diseases and for the preparation of gargles [11, 23,
24, 36]. The decoction of roots and leaves or roots alone are
also traditionally used to tone up the uterus after childbirth
in order to strengthen the womb and accelerate wound heal-
ing. Other than that, women also use this herb for excessive
menstrual bleeding and cramps, to relieve postmenstrual
syndrome, stomach ache, and white discharge, and to en-
hance fertility [23]. Its ﬂowers, seeds, and leaves are used
to reduce white vaginal discharge and indigestion [9]. The
ﬂowers of M. malabathricum are also used as a nervous seda-
tive and for hemorrhoidal bleeding [9]. The combination of
leaves and ﬂowers is used as astringent in leukorrhea and
chronic diarrhea [9]. Despite being a traditional medicinal
herb that is widely used, particularly, in Malay culture,
there is not much scientiﬁc study carried out on M. mala-
bathricum.
2.2.ReportsontheUsesofM.malabathricumbyVariousCom-
munities/Tribes. The list of medicinal uses of M. malabathri-
cum according to the diﬀerent communities or tribes re-
ported around the world is shown in Table 2(b). According
to Elliott and Brimacombe [37] the cold infusion of M.
malabthricum ﬂowers is an optional ingredient added to
an oral remedy for anaemia associated with gastrointestinal
bleeding and epigastric pain. The Talang Mamak peoples of
Riau province, Sumatra, Indonesia, used the ground leaf and
applied it as a compress to cuts and wounds [8]. A survey
of the Malay ethnomedico botany in the Machang district,
Kelantan, Malaysia, revealed the application of M. mala-
bathricum fruits juice on dry lip [38] while in the GemencehEvidence-Based Complementary and Alternative Medicine 5
Table 2: (a) Medicinal uses of M. malabathricum according to its part. (b) Medicinal uses of M. malabathricum according to several com-
munities/tribes reported around the world.
(a)
Plant parts Medicinal uses Reference
Leaves
Leaves are chewed up, pounded, and applied as paste on cuts or
wounds or ﬁnely chopped up and squeezed to apply the juice onto
the wound to stop bleeding
Latiﬀ and Zakri [29];
Jaganath and Ng [25];
Zakaria et al. [30]
Leaves are used to prevent scarring from smallpox, to treat dysentery,
diarrhoea, piles, and as a tonic Sharma et al. [11]
Young leaves are eaten to treat diarrhea Jaganath and Ng [25]
Young premature leaves are consumed raw to cure dysentery Sajem and Gosai [31]
Leaves are also useful to treat ulcers, gastric ulcers, scar, pimple, and
b l a c ks p o ta ts k i n Loh´ ezic-Le D´ ev´ ehat et al. [32]
Combination of leaves and roots in powder form is applied to
wounds and pox scars to aid the healing process or used to relieve the
discomfort of hemorrhoids
Burkill [24]; Fazlin et al. [7]
Powdered leaves alone is used as astringent for dysentery Umali-Stuart and
Stiuart-Santiago [9]
Juice of leaves and roots is used as a digestive aid Umali-Stuart and
Stiuart-Santiago [9]
Combination of leaves and ﬂowers is used in the treatment of cholera,
diarrhoea, prolonged fever, dysentery, leucorrhoea, wounds, and skin
diseases and for the preparation of gargles
Perry [36]; Burkill [24];
Koay [23]; Sharma et al. [11]
Combination of leaves and ﬂowers is used as astringent in leukorrhea
and chronic diarrhea
Umali-Stuart and
Stiuart-Santiago [9]
Shoots
Shoots are ingested to treat puerperal infections, high blood pressure,
and diabetes Burkill [24]; Koay [23]
Juice of shoots is used as a mouthwash to relieve a toothache or to
treat leukorrhea
Roots
Roots are used as mouthwash to relieve a toothache and to treat
epilepsy
Burkill [24];
Jaganath and Ng [25];
Loh´ ezic-Le D´ ev´ ehat et al. [32]
Roots are given to postpartum women to aid healing and womb
strengthening
Fazlin et al. [7]; Jaganath and
Ng [25]; Zakaria et al. [30]
Roots are used to alleviate rheumatism, arthritis, and tenderness in
the legs Burkill [24]; Koay [23]
Decoction of roots is used to treat diarrhea Lin [33]
Juice of roots is applied to lessen the soreness due to thrush in
children Burkill [24]; Koay [23]
Combination of roots and leaves in a form of decoction or roots
alone are used to tone up the uterus after childbirth in order to
strengthen the womb and accelerate wound healing, reduce excessive
menstrual bleeding and cramps, relieve postmenstrual syndrome,
stomach ache, and white discharge, and enhance fertility
Koay [23]
Barks Barks are useful for the treatment of various skin diseases Jain and De Filipps [34]
Flowers
Flowers are used to treat cancer Mohandoss and Ravindran
[35]
Flowers are used as a nervous sedative and for hemorrhoidal bleeding Umali-Stuart and
Stiuart-Santiago [9]
Combination of ﬂowers, seeds, and leaves is used to reduce white
vaginal discharge and indigestion Jaganath and Ng [25]6 Evidence-Based Complementary and Alternative Medicine
(b)
Communities/tribes Country Medicinal uses Reference
Gayo and Alas Aceh, Sumatra, Indonesia
The cold infusion of M. malabthricum ﬂowers is
an optional ingredient added to an oral remedy
for anaemia associated with gastrointestinal
bleeding and epigastric pain
Elliott and Brimacombe
[37]
Talang Mamak Riau, Sumatra, Indonesia The ground leaves are applied as a compress to
cuts and wounds Grosvenor et al. [8]
Malay
Machang, Kelantan,
Malaysia The fruit juice is applied on dry lips Ong and Nordiana [38]
Gemenceh, Negri
Sembilan, Malaysia
The pounded leaves are applied onto wounds to
accelerate healing Ong and Nordiana [39]
Jah Hut Jerantut, Pahang, Malaysia The roots are applied as decoction to treat
diarrhea Lin [33]
Lakher and Pawi Mizoram, India The decoction of the leaves or its juice is taken
orally to treat diarrhoea and dysentery Sharma et al. [11]
Meitei Manipur and Mayurbhanj,
Orissa, India
The bark and leaves are used for treating skin
troubles, leukorrhea, diarrhea, and dysentry Thatoi et al. [14]
Didayi Malkangiri, Orissa, India The leaves are applied externally as paste to treat
cuts and wounds Pattanaik et al. [13]
Sundanese Bogor, West Java, Indonesia
The leaves is used as topical application or oral
ingestion to treat toothache and for postpartum
remedy
Roosita et al. [40]
Marmas Bandarban, Bangladesh The root juice is used to treat jaundice Rahmatullah et al. [18]
Garo Netrakona, Bangaldesh The leaf juice is used as a diuretic and to treat
various urinary problems Rahmatullah et al. [19]
Murong Rangamati, Bangladesh T h er o o tj u i c eo rw a t e re x t r a c to fb o i l e dr o o t sa r e
used orally to treat leukorrhea Rahmatullah et al. [20]
Naga Manipur, India The fresh and dry leaves are used to treat cuts and
wounds, stomach disorder, and fever Ringmichon et al. [15]
Tahiti The plant is used to treat diarrhea and dysentery
with its bark decoction used as gargle
Umali-Stuart and
Stiuart-Santiago [9]
district, Negri Sembilan, Malaysia, the Malays applied M.
malabathricum pounded leaves onto wounds to accelerate
healing [39]. The Jah Hut tribe in Jerantut district, Pahang,
Peninsular, Malaysia, used the roots of M. malabathricum as
decoction to treat diarrhea [33] .T h en a t i v ep e o p l e so fM i z o -
ram, India, used the decoction of the leaf or its juice, which
is taken orally, in the treatment of diarrhoea and dysentery
[11]. The Meitei community living in Manipur district in
India and other tribes living in the Similipal Biosphere
Reserve, situated in Mayurbhanj district of Orissa, India,
used the bark and leaves of M. malabathricum for treating
skin troubles, leukorrhea, diarrhea, and dysentery [14] while
the Didayi tribe of Malkangiri district of Orissa, India, used
the leaf externally as paste to treat cuts and wounds [13].
The Sundanese community of the West Java, Indonesia,
uses the leaf of M. malabathricum as topical application
or oral ingestion to treat toothache and for postpartum
remedy [40]. The Marmas community of Naikhongcharri,
Bandarban district, Bangladesh, used the root juice to
treat jaundice [18]. The Garo tribal community living in
Netrakona district, Bangladesh, used the leaf juice as diuretic
and to treat various urinary problems [19]. The Murong
tribes residing in the Rangamati district in the Chittagong
Hill Tracts region, Bangladesh, used the squeezed juice from
the roots or water extract of the boiled roots orally to treat
leukorrhea [20]. In Tahiti, M. malabathricum is used to treat
diarrhea and dysentery with its bark decoction used as gargle
[9]. The Naga tribe of Manipur district, India, used the fresh
anddryleavesofM.malabathricumtotreatcutsandwounds,
stomach disorder, and fever [15].
3.Phytochemical Constituents
Various phytochemical groups and constituents have been
identiﬁed in M. malabathricum since 1968 and are strongly
associated with its ethnomedicinal values (Tables 3(a) and
3(b)). Earlier study by Lowry [41] showed the presence
of ellagic acid and anthocyanin (e.g., malvidin-3,5-digluco-
side) in the methanol extract of M. malabathricum barks
(MMMBk) and aqueous extract of M. malabathricum ﬂow-
ers (AMMFw), respectively. Meanwhile, Lowry [42] also
reported the presence of anthocyanins (e.g., cyanidin- (Cy-)
3-glucoside and Cy-3,5-diglucoside) in the water extract
of M. malabathricum fruits (WMMFr). Manzoor-I-Khuda
et al. [43] reported the isolation of β-sitosterol and a triter-
penoid designated as melastomic acid (5-hydroxylup-20(29)
-en-28-oic acid) from the ethanolic extract of M. mala-
bathricum roots (EMMR). Dinda and Saha [44]r e p o r t e dEvidence-Based Complementary and Alternative Medicine 7
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n
s
+
L
e
a
v
e
s
Z
a
k
a
r
i
a
e
t
a
l
.
[
3
0
]
;
S
i
m
a
n
j
u
n
t
a
k
[
5
7
]
+
L
e
a
v
e
s
a
n
d
r
o
o
t
s
F
a
r
a
v
a
n
i
[
5
8
]
A
l
k
a
l
o
i
d
s
−
L
e
a
v
e
s
Z
a
k
a
r
i
a
e
t
a
l
.
[
3
0
]
S
t
e
r
o
i
d
s
+
L
e
a
v
e
s
Z
a
k
a
r
i
a
e
t
a
l
.
[
3
0
]
;
S
i
m
a
n
j
u
n
t
a
k
[
5
7
]
+
L
e
a
v
e
s
a
n
d
r
o
o
t
s
F
a
r
a
v
a
n
i
[
5
8
]
G
l
y
c
o
s
i
d
e
s
+
L
e
a
v
e
s
S
i
m
a
n
j
u
n
t
a
k
[
5
7
]
+
L
e
a
v
e
s
a
n
d
r
o
o
t
s
F
a
r
a
v
a
n
i
[
5
8
]
P
h
e
n
o
l
i
c
s
+
L
e
a
v
e
s
a
n
d
r
o
o
t
s
F
a
r
a
v
a
n
i
[
5
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(
b
)
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
E
l
l
a
g
i
c
a
c
i
d
A
O
O
O
O
O
H
O
H
H
O
O
H
B
a
r
k
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
L
o
w
r
y
[
4
1
]
F
l
o
w
e
r
s
E
t
h
y
l
a
c
e
t
a
t
e
-
s
o
l
u
b
l
e
p
a
r
t
o
f
a
9
0
%
a
q
u
e
o
u
s
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
W
o
n
g
e
t
a
l
.
[
5
3
]
;
A
l
i
e
t
a
l
.
[
5
2
]
C
y
a
n
i
d
i
n
-
3
-
g
l
u
c
o
s
i
d
e
A
O
O
H
O
H
O
H
H
O
O
O
O
H
O
H
H
O
H
O
+
C
l
−
F
r
u
i
t
s
W
a
t
e
r
e
x
t
r
a
c
t
L
o
w
r
y
[
4
1
]
C
y
a
n
i
d
i
n
-
3
,
5
-
d
i
g
l
u
c
o
s
i
d
e
B
O
O
H
O
H
H
O
O
O
O
H
O
O
H
O
H
O
H
O
H
O
O
H
O
H
O
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
M
a
l
v
i
d
i
n
-
3
,
5
-
d
i
g
l
u
c
o
s
i
d
e
A
O
+
O
O
O
O
O
H
O
O
O
H
H
O
H
O
O
H
O
H
H
O
O
H
O
H
O
H
F
l
o
w
e
r
A
q
u
e
o
u
s
e
x
t
r
a
c
t
L
o
w
r
y
[
4
2
]
β
-
S
i
t
o
s
t
e
r
o
l
A
H
O
H
H
H
H
R
o
o
t
s
E
t
h
a
n
o
l
e
x
t
r
a
c
t
M
a
n
z
o
o
r
-
I
-
K
h
u
d
a
e
t
a
l
.
[
4
3
]
A
e
r
i
a
l
s
H
e
x
a
n
e
p
a
r
t
o
f
t
h
e
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
P
o
n
g
p
r
o
m
e
t
a
l
.
[
5
0
]
L
e
a
v
e
s
(
h
e
x
a
n
e
f
r
a
c
t
i
o
n
o
f
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
)
N
u
r
e
s
t
r
i
e
t
a
l
.
[
5
1
]
L
e
a
v
e
s
9
0
%
a
q
u
e
o
u
s
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
A
l
i
e
t
a
l
.
[
5
2
]
β
-
S
i
t
o
s
t
e
r
o
l
-
3
-
O
-
β
-
D
-
g
l
u
c
o
p
y
r
a
n
o
s
i
d
e
E
H
O
H
O
O
O
O
H
O
H
L
e
a
v
e
s
H
e
x
a
n
e
f
r
a
c
t
i
o
n
o
f
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
N
u
r
e
s
t
r
i
e
t
a
l
.
[
5
1
]
L
e
a
v
e
s
9
0
%
a
q
u
e
o
u
s
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
s
A
l
i
e
t
a
l
.
[
5
2
]
U
r
s
o
l
i
c
a
c
i
d
A
H
O
H
H
H
O
O
H
L
e
a
v
e
s
a
n
d
ﬂ
o
w
e
r
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
D
a
s
a
n
d
K
o
t
o
k
y
[
4
6
]
A
e
r
i
a
l
s
H
e
x
a
n
e
p
a
r
t
o
f
t
h
e
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
P
o
n
g
p
r
o
m
e
t
a
l
.
[
5
0
]
L
e
a
v
e
s
M
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
N
u
r
e
s
t
r
i
e
t
a
l
.
[
5
1
]
L
e
a
v
e
s
9
0
%
a
q
u
e
o
u
s
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
A
l
i
e
t
a
l
.
[
5
2
]
L
e
a
v
e
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
F
a
r
a
v
a
n
i
[
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
2
-
H
y
d
r
o
x
y
u
r
s
o
l
i
c
a
c
i
d
A
H
O
H
O
H
H
H
O
O
H
L
e
a
v
e
s
M
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
)
N
u
r
e
s
t
r
i
e
t
a
l
.
[
5
1
]
L
e
a
v
e
s
9
0
%
a
q
u
e
o
u
s
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
A
l
i
e
t
a
l
.
[
5
2
]
A
s
i
a
t
i
c
a
c
i
d
A
H
H
H
O
O
H
O
H
H
O
H
O
L
e
a
v
e
s
M
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
N
u
r
e
s
t
r
i
e
t
a
l
.
[
5
1
]
L
e
a
v
e
s
9
0
%
a
q
u
e
o
u
s
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
A
l
i
e
t
a
l
.
[
5
2
]
S
t
e
a
r
i
c
a
c
i
d
A
H
O
O
A
e
r
i
a
l
s
H
e
x
a
n
e
p
a
r
t
o
f
t
h
e
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
P
o
n
g
p
r
o
m
e
t
a
l
.
[
5
0
]
p
-
H
y
d
r
o
x
y
b
e
n
z
o
i
c
a
c
i
d
A
O
H
O
O
H
L
e
a
v
e
s
a
n
d
ﬂ
o
w
e
r
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
D
a
s
a
n
d
K
o
t
o
k
y
[
4
6
]
G
a
l
l
i
c
a
c
i
d
A
O
H
O
H
H
O
H
O
O
L
e
a
v
e
s
a
n
d
ﬂ
o
w
e
r
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
D
a
s
a
n
d
K
o
t
o
k
y
[
4
6
]
L
e
a
v
e
s
a
n
d
ﬂ
o
w
e
r
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
F
a
r
a
v
a
n
i
[
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
K
a
e
m
p
f
e
r
o
l
A
O
H
O
O
H
H
O
O
H
O
L
e
a
v
e
s
a
n
d
ﬂ
o
w
e
r
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
D
a
s
a
n
d
K
o
t
o
k
y
[
4
6
]
F
l
o
w
e
r
s
E
t
h
y
l
a
c
e
t
a
t
e
s
o
l
u
b
l
e
p
a
r
t
o
f
a
9
0
%
a
q
u
e
o
u
s
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
W
o
n
g
e
t
a
l
.
[
5
3
]
;
A
l
i
e
t
a
l
.
[
5
2
]
L
e
a
v
e
s
n
-
H
e
x
a
n
e
,
e
t
h
y
l
a
c
e
t
a
t
e
a
n
d
m
e
t
h
a
n
o
l
e
x
t
r
a
c
t
s
K
o
a
y
[
2
3
]
K
a
e
m
p
f
e
r
o
l
-
3
-
O
-
β
-
D
-
g
l
u
c
o
s
i
d
e
A
O
H
O
O
H
O
O
H
O
O
H
O
H
O
O
H
O
H
F
l
o
w
e
r
s
E
t
h
y
l
a
c
e
t
a
t
e
e
x
t
r
a
c
t
K
o
a
y
[
2
3
]
F
l
o
w
e
r
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
K
o
a
y
[
2
3
]
K
a
e
m
p
f
e
r
o
l
-
3
-
O
-
α
-
L
-
r
h
a
m
n
o
p
y
r
a
n
o
s
i
d
e
A
O
H
O
O
H
O
H
O
O
H
O
H
O
O
H
F
l
o
w
e
r
s
E
t
h
y
l
a
c
e
t
a
t
e
-
s
o
l
u
b
l
e
p
a
r
t
o
f
a
n
9
0
%
a
q
u
e
o
u
s
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
W
o
n
g
e
t
a
l
.
[
5
3
]
;
A
l
i
e
t
a
l
.
[
5
2
]
K
a
e
m
p
f
e
r
o
l
-
3
-
O
-
β
-
D
-
g
l
u
c
o
p
y
r
a
n
o
s
i
d
e
A
H
O
H
O
H
O
O
O
H
O
O
H
O
O
O
H
O
H
F
l
o
w
e
r
s
E
t
h
y
l
a
c
e
t
a
t
e
s
o
l
u
b
l
e
p
a
r
t
o
f
a
n
9
0
%
a
q
u
e
o
u
s
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
W
o
n
g
e
t
a
l
.
[
5
3
]
;
A
l
i
e
t
a
l
.
[
5
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
K
a
e
m
p
f
e
r
o
l
-
3
-
O
-
(
2
 
 
,
6
 
 
-
d
i
-
O
-
p
-
t
r
a
n
s
-
c
o
u
m
a
r
o
y
l
)
-
β
-
g
l
u
c
o
s
i
d
e
C
O
O
O
H
H
O
O
H
O
O
O
C
=
O
O
H
O
H
O
H
O
C
O
O
H
F
l
o
w
e
r
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
K
o
a
y
[
2
3
]
L
e
a
v
e
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
S
u
s
a
n
t
i
e
t
a
l
.
[
5
6
]
1
,
4
,
6
-
T
r
i
-
O
-
g
a
l
l
o
y
l
-
β
-
D
-
g
l
u
c
o
s
i
d
e
R
1
 
=
 
H
,
 
R
2
 
=
 
R
3
 
=
 
G
G
=
C
O
O
H
O
H
O
H
O
C
H
2
O
R
3
R
2
R
1
O
H
O
O
O
G
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
8
]
1
,
2
,
4
,
6
-
T
e
t
r
a
-
O
-
g
a
l
l
o
y
l
-
β
-
D
-
g
l
u
c
o
s
i
d
e
R
1
 
=
 
R
2
 
=
 
R
3
 
=
 
G
G
=
C
O
O
H
O
H
O
H
R
2
R
1
C
H
2
O
R
3
O
O
H
O
O
G
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
M
a
l
a
b
a
t
h
r
i
n
B
D
O
C
H
2
O
R
4
O
O
C
O
H
O
H
O
H
O
H
O
O
H
O
H
O
O
H
O
H
H
O
O
H
O
O
C
O
C
O
O
O
H
2
C
O
O
C
O
H
O
H
O
G
l
u
c
o
s
e
-
I
G
l
u
c
o
s
e
-
I
I
G
 
=
C
O
O
H
O
H
O
H
O
H
H
O
O
H
O
H
C
O
C
O
(
S
)
-
H
H
D
P
 
=
O
H
O
H
O
H
O
C
H
O
(
B
)
-
O
G
 
O
H
(
S
)
-
H
H
D
P
 
G
R
3
R
5
R
2
R
1
R
5
R
4
R
3
R
2
R
1
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
8
]
M
a
l
a
b
a
t
h
r
i
n
C
D
O
H
 
(
B
)
-
O
G
(
S
)
-
H
H
D
P
 
G
O
C
H
2
O
R
4
O
O
C
O
H
O
H
O
H
O
H
O
O
H
O
H
O
O
H
O
H
H
O
O
H
O
O
C
O
C
O
O
O
H
2
C
O
O
C
O
H
O
H
O
G
l
u
c
o
s
e
-
I
G
l
u
c
o
s
e
-
I
I
G
 
=
C
O
O
H
O
H
O
H
O
H
H
O
O
H
O
H
C
O
C
O
(
S
)
-
H
H
D
P
 
=
O
H
O
H
O
H
O
C
H
O
R
3
R
5
R
2
R
1
R
5
R
4
R
3
R
2
R
1
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
M
a
l
a
b
a
t
h
r
i
n
D
D
O
H
O
H
O
H
O
H
H
O
H
O
H
O
H
O
C
O
O
H
C
O
O
O
C
H
2
O
O
C
O
O
C
O
H
O
H
O
O
H
O
C
O
O
H
O
H
O
O
H
O
H
C
O
O
O
O
O
G
O
C
O
O
H
O
O
H
H
O
R
O
O
C
O
H
H
O
O
C
O
H
H
O
O
H
O
H
C
H
2
O
G
R
 
=
 
C
H
3
G
=
C
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
8
]
S
t
r
i
c
t
i
n
i
n
A
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
C
a
s
u
a
r
i
c
t
i
n
A
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
H
O
O
O
O
O
O
O
O
H
O
O
O
H
O
O
H
H
O
H
O
H
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
8
]
P
e
d
u
n
c
u
l
a
g
i
n
A
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
O
O
O
O
H
O
O
O
H
O
O
H
H
O
H
O
H
O
H
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
8
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
P
t
e
r
o
c
a
r
i
n
i
n
C
D
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
H
O
C
O
O
O
O
O
O
O
O
C
 
 
H
O
H
O
H
O
O
H
2
C
C
O
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
8
]
N
o
b
o
t
a
n
i
n
B
A
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
8
]
N
o
b
o
t
a
n
i
n
D
D
H
O
H
O
H
O
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
O
O
O
O
O
O
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
N
o
b
o
t
a
n
i
n
s
G
D
O
H
H
O
O
H
O
O
H
O
O
O
H
O
H
O
H
O
H
O
H
O
O
O
O
O
O
H
O
H
H
O
O
O
O
O
O
H
H
O
H
O
H
O
H
O
H
O
O
H
O
H
O
H
O
O
H
O
H
H
O
H
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
8
]
N
o
b
o
t
a
n
i
n
s
H
D
O
H
O
H
O
H
O
H
O
H
O
O
O
O
O
O
O
H
O
H
H
O
O
O
O
O
O
H
H
O
H
O
H
O
H
O
H
O
O
H
O
H
O
H
O
O
O
O
O
O
H
O
H
O
H
O
O
H
H
O
H
O
H
O
H
O
O
O
H
H
O
H
O
H
O
O
O
O
H
H
O
O
H
O
O
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
8
]18 Evidence-Based Complementary and Alternative Medicine
(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
N
o
b
o
t
a
n
i
n
J
D
C
O
O
H
H
O
H
O
H
O
H
O
O
H
C
O
O
O
C
H
2
O
O
C
O
O
G
H
O
H
O
O
H
H
O
O
H
O
H
O
O
H
O
H
C
O
O
C
O
O
O
G
O
C
O
O
C
O
H
O
H
O
O
H
O
H
O
O
H
H
O
C
O
O
O
C
O
O
C
H
O
H
H
O
H
O
O
H
O
O
C
H
O
O
H
O
H
H
O
H
O
O
H
O
C
O
H
H
O
H
O
O
C
H
2
O
C
H
2
O
H
O
H
G
=
C
O
O
H
O
H
O
H
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
8
]
M
a
l
a
b
a
t
h
r
i
n
s
A
E
H
O
H
O
O
H
H
O
C
O
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
C
O
H
2
C
O
O
O
C
O
H
O
H
O
O
H
O
O
H
O
O
C
O
C
H
O
O
O
C
O
O
H
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
M
a
l
a
b
a
t
h
r
i
n
E
D
O
H
O
H
H
O
C
O
O
O
H
O
O
H
O
H
O
H
O
H
O
H
O
O
O
O
O
H
O
H
O
H
O
O
H
O
O
O
O
O
H
O
H
O
H
O
H
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
9
]
M
a
l
a
b
a
t
h
r
i
n
s
F
D
O
H
H
O
H
O
H
O
H
O
H
O
H
O
H
O
O
O
O
O
H
O
O
O
O
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
O
O
O
O
O
O
H
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
9
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
C
a
s
u
a
r
i
n
i
n
A
H
O
H
O
H
O
H
O
H
O
H
O
H
O
O
O
O
O
O
O
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
O
O
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
9
]
(
-
)
-
E
p
i
c
a
t
e
c
h
i
n
g
a
l
l
a
t
e
A
O
O
O
H
H
O
H
O
H
O
O
H
O
H
O
O
H
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
9
]Evidence-Based Complementary and Alternative Medicine 21
(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
(
-
)
-
E
p
i
c
a
t
e
c
h
i
n
A
O
H
H
O
O
H
O
O
H
O
H
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
9
]
S
t
a
c
h
y
u
r
i
n
A
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
9
]
P
r
o
c
y
a
n
i
d
i
n
B
5
A
O
O
O
O
O
O
O
O
O
O
O
O
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
9
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
P
r
o
c
y
a
n
i
d
i
n
B
2
A
O
O
O
O
O
O
O
O
O
O
O
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
9
]
S
t
e
n
o
p
h
y
l
l
a
n
i
n
A
C
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
O
O
O
O
O
O
O
O
O
H
O
H
O
O
H
O
H
O
H
O
H
O
H
O
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
S
t
e
n
o
p
h
y
l
l
a
n
i
n
B
D
H
O
O
H
H
O
H
O
O
H
O
H
C
O
C
O
C
O
C
O
O
O
H
2
C
O
H
O
H
O
H
O
H
O
O
H
O
O
H
H
O
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
O
C
R
R
 
=
 
H
O
R

=
R

L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
9
]
A
l
i
e
n
a
n
i
n
B
E
O
H
O
H
H
O
O
H
H
O
H
O
C
O
C
O
H
3
C
O
O
O
C
O
H
O
H
O
H
O
H
O
H
O
H
O
O
C
C
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
O
H
H
H
O
O
H
H
O
C
O
C
O
O
C
O
H
O
H
O
H
C
O
O
O
O
C
O
O
O
C
H
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
9
]
B
r
e
v
i
f
o
l
i
n
c
a
r
b
o
x
y
l
i
c
a
c
i
d
E
O
O
O
H
O
O
H
O
H
H
O
O
C
L
e
a
v
e
s
7
0
%
a
c
e
t
o
n
e
e
x
t
r
a
c
t
Y
o
s
h
i
d
a
e
t
a
l
.
[
4
9
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
α
-
A
m
y
r
i
n
A
H
O
H
H
H
L
e
a
v
e
s
H
e
x
a
n
e
f
r
a
c
t
i
o
n
o
f
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
N
u
r
e
s
t
r
i
e
t
a
l
.
[
5
1
]
S
t
e
m
s
n
-
H
e
x
a
n
e
e
x
t
r
a
c
t
K
o
a
y
[
2
3
]
L
e
a
v
e
s
n
-
H
e
x
a
n
e
e
x
t
r
a
c
t
S
u
s
a
n
t
i
e
t
a
l
.
[
5
6
]
U
v
a
o
l
A
H
O
H
O
H
H
H
L
e
a
v
e
s
n
-
H
e
x
a
n
e
f
r
a
c
t
i
o
n
o
f
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
N
u
r
e
s
t
r
i
e
t
a
l
.
[
5
1
]
Q
u
e
r
c
e
t
i
n
A
O
H
O
H
O
H
H
O
H
O
O
L
e
a
v
e
s
H
e
x
a
n
e
f
r
a
c
t
i
o
n
o
f
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
N
u
r
e
s
t
r
i
e
t
a
l
.
[
5
1
]
F
l
o
w
e
r
s
E
t
h
y
l
a
c
e
t
a
t
e
s
o
l
u
b
l
e
p
a
r
t
o
f
a
9
0
%
a
q
u
e
o
u
s
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
W
o
n
g
[
5
3
]
;
A
l
i
e
t
a
l
.
[
5
2
]
L
e
a
v
e
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
N
a
z
l
i
n
a
e
t
a
l
.
[
5
5
]
L
e
a
v
e
s
E
t
h
y
l
a
c
e
t
a
t
e
e
x
t
r
a
c
t
S
u
s
a
n
t
i
e
t
a
l
.
[
5
6
]
Q
u
e
r
c
i
t
r
i
n
A
O
H
O
H
O
O
O
O
O
O
O
O
L
e
a
v
e
s
H
e
x
a
n
e
f
r
a
c
t
i
o
n
o
f
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
N
u
r
e
s
t
r
i
e
t
a
l
.
[
5
1
]
L
e
a
v
e
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
N
a
z
l
i
n
a
e
t
a
l
.
[
5
5
]
L
e
a
v
e
s
E
t
h
y
l
a
c
e
t
a
t
e
e
x
t
r
a
c
t
S
u
s
a
n
t
i
e
t
a
l
.
[
5
6
]
L
e
a
v
e
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
R
u
t
i
n
A
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
L
e
a
v
e
s
H
e
x
a
n
e
f
r
a
c
t
i
o
n
o
f
m
e
t
h
a
n
o
l
i
c
e
x
t
r
a
c
t
N
u
r
e
s
t
r
i
e
t
a
l
.
[
5
1
]
L
e
a
v
e
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
N
a
z
l
i
n
a
e
t
a
l
.
[
5
5
]
B
e
t
u
l
i
n
i
c
a
c
i
d
A
H
H
H
H
O
O
H
O
H
R
o
o
t
s
n
-
H
e
x
a
n
e
e
x
t
r
a
c
t
K
o
a
y
[
2
3
]
F
r
u
i
t
s
E
t
h
y
l
a
c
e
t
a
t
e
e
x
t
r
a
c
t
K
o
a
y
[
2
3
]
N
a
r
i
n
g
e
n
i
n
A
O
O
H
O
O
H
O
H
F
l
o
w
e
r
s
E
t
h
y
l
a
c
e
t
a
t
e
e
x
t
r
a
c
t
K
o
a
y
[
2
3
]
P
a
t
r
i
s
c
a
b
r
a
t
i
n
e
A
N
H
N
H
H
O
O
H
O
O
L
e
a
v
e
s
n
-
H
e
x
a
n
e
e
x
t
r
a
c
t
S
u
s
a
n
t
i
e
t
a
l
.
[
5
6
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(
b
)
C
o
n
t
i
n
u
e
d
.
N
a
m
e
o
f
c
o
m
p
o
u
n
d
S
t
r
u
c
t
u
r
e
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
R
e
f
e
r
e
n
c
e
A
u
r
a
n
a
m
i
d
e
D
H
N
O
O
N
H
O
O
L
e
a
v
e
s
n
-
H
e
x
a
n
e
e
x
t
r
a
c
t
S
u
s
a
n
t
i
e
t
a
l
.
[
5
6
]
1
-
O
c
t
y
l
d
e
c
a
n
o
a
t
e
A
O
O
N
A
N
A
D
i
n
d
a
a
n
d
S
a
h
a
[
4
5
,
4
7
]
H
e
x
a
c
o
s
a
n
o
i
c
a
c
i
d
H
O
O
L
e
a
v
e
s
a
n
d
r
o
o
t
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
F
a
r
a
v
a
n
i
[
5
8
]
M
e
l
a
s
t
o
m
i
c
a
c
i
d
N
A
R
o
o
t
s
E
t
h
a
n
o
l
e
x
t
r
a
c
t
M
a
n
z
o
o
r
-
I
-
K
h
u
d
a
e
t
a
l
.
[
4
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the isolation of 1-octyl docosanoate and 11-methyl-1-
tricontanol while Dinda and Saha [45] reported the presence
of fatty acids and sterols. Das and Kotoky [46]r e p o r t e d
the isolation of a new aliphatic constituent, namely, 32-
methyl-1-tritriacontanol, together with ursolic acid, p-hydr-
oxybenzoic acid and gallic acid, and kaempferol from the
leaves and ﬂowers of M. malabathricum. Compounds like
kaempferol-3-O-β-D-xyloside, quercetin-3-O-α-L-rhamno-
syl-(1→2)-β-D-galactoside, ﬂavan-3-ol, 4 -methylpeonidin
-7-O-β-D-glucoside, anthocyanins, and tannins have also
been isolated from the aerial part of M. malabathricum [35,
47].
Yoshida et al. [48] reported the isolation of isoquercitrin
6  -0-gallate, a ﬂavonoid glycoside, three new dimeric hydro-
lysable tannins, namely, malabathrins B, C, and D, and the
eleven known hydrolysable tannins from the 70% acetone
extract of M. malabathricum leaves (AcMML). Among the
eleven known tannins, seven were monomeric hydrolysable
tannins, namely, 1,4,6-tri-O-galloyl-β-D-glucoside, 1,2,4,6-
tetra-O-galloyl-β-D-glucoside, strictinin, casuarictin, ped-
unculagin, nobotanin D, and pterocarinin C while the other
four were hydrolysable tannin oligomers which were iden-
tiﬁed as nobotanins B, G, and H (dimers) and nobotanin
J (trimer). In the same year, Yoshida et al. [49] successfully
isolated malabathrins A, E, and F, new complex tannins in
whichanellagitanninandaﬂavan-3-olareboundbyaC-gly-
cosidic linkage belonging to type II+ tannins, and other
tannins, namely, casuarinin, (-)-epicatechin gallate, (-)-epi-
catechin, stachyurin, procyanidin B-5 and B-2, stenophyl-
lanins A and B, alienanin B, and brevifolincarboxylic acid.
The chromatographic separation of the hexane part of
the methanolic extract of M. malabathricum aerial parts
(MMMAp) led to the identiﬁcation of stearic acid, β-sito-
sterol and ursolic acid [50]. On the other hand, Nurestri
et al. [51] have successfully isolated three pentacyclic tri-
terpenoids, namely, ursolic acid, 2-hydroxyursolic acid and
asiatic acid, as well as glycerol-1,2-dilinolenyl-3-O-β-D-
galactopyranoside and glycerol 1,2-dilinolenyl- 3-O-(4,6-di-
O-isopropylidene)-β-D-galactopyranoside from the metha-
nolic extract of M. malabathricum leaves (MMML) with
light pink-magenta petals [51]. Nurestri et al. [51] also iso-
lated β-sitosterol, α-amyrin, uvaol, quercetin, quercitrin,
rutin, and sitosterol-3-O-β-D-glucopyranoside from the
hexane fraction of MMML. Ali et al. [52] isolated three urs-
12-ene pentacyclic triterpenoids, namely, ursolic acid, 2α-
hydroxyursolic acid and asiatic acid, β-sitosterol 3-O - β-
Dglucopyranoside, glycerol 1,2-dilinolenyl-3-O-β-D-galac-
topyranoside and glycerol 1,2-dilinolenyl-3-O-(4,6-O-iso-
propylidene)-β-D-galactopyranoside from the 90% aque-
ous methanolic extracts of M. malabathricum fresh leaves
(AMMML). In addition, subjection of the ethyl acetate-
soluble part of an 90% aqueous methanolic extract of M.
malabathricum ﬂowers (AMMMFw) to isolation and identi-
ﬁcation of bioactive compounds yielded ellagic acid and
six ﬂavonoids which were identiﬁed as quercetin, kaempfe-
rol, kaempferol 3-O-α-L-rhamnopyranoside, kaempferol
3-O-β-D-glucopyranoside, kaempferol 3-O-β-D-galactopy-
ranoside, and kaempferol 3-O-(2  ,6  -di-O-E-p-coumaryl)-
β-D-galactopyranoside [53, 54]. Koay [23] also cited that
the n-hexane (HMML), ethyl acetate (EAMML), and
MMML extracts of M. malabathricum leaves yielded three
new compounds, 2,5,6-trihydroxynaphtoic carbonic acid,
methyl-2,5,6-trihydroxynaphtalene carbonate, and ﬂavonol
glycoside derivative. The n-hexane extract of M. malaba-
thricum roots (HMMR) contained betulinic acid, serrat-
14-en-16-one, and 2-(2 -hydroxyvinyl)-1-methyl-4-propo-
xyphthalate. The ethyl acetate extract of M. malabathricum
ﬂowers (EAMMFw) yielded three compounds, kaempferol-
3-O-β-D-glucoside, kaempferol, and naringenin, while the
methanol extract of M. malabathricum ﬂowers (MMMFw)
was found to contain kaempferol-3-O-(2  ,6  -di-O-p-trans-
coumaroyl)-glucoside and kaempferol-3-O-β-D-glucoside.
The ethyl acetate extract of M. malabathricum fruits
(EAMMFr) aﬀorded betulinic acid, while the n-hexane ex-
tractofthestemsproducedα-amyrin.Nazlinaetal.[55]s uc-
cessfully isolated rutin, quercitrin, and quercetin from the
MMML using TLC assay. In addition, Susanti et al. [56]
also reported the isolation of a triterpene (α-amyrin) and
two amides (patriscabatrine and auranamide) from the
HMML, two ﬂavonoids (quercetin and quercitrin) from the
EAMML, and two ﬂavonoids (quercitrin and kaempferol-
3-O-(2  ,6  -di-O-p-trans-coumaroyl)-β-glucoside) from the
MMML after successive extraction of the leaves of M. mala-
bathricum with white petals. Zakaria et al. [30] reported the
presence of ﬂavonoids, triterpenes, tannins, saponins, and
steroids, but no alkaloids in the leaves of M. malabathricum
found in Malaysia. Simanjuntak [57] also reported the
presenceofﬂavonoids,saponins,tannins,glycosides,andste-
roids/triterpenoids in the leaves of M. malabathricum col-
lected in Sumatera, Indonesia. Faravani [58] identiﬁed sev-
eral secondary metabolites from the MMML and methanol
extract of M. malabathricum roots (MMMR), such as
hexacosanoic acid, gallic acid, ﬂavonoids and ﬂavonoids gly-
cosides, phenolics, triterpenes, tannins, saponins, and ste-
roids. Further analyses of the MMML yielded 3 urs-12-ene
pentacyclic triterpenoids, namely, ursolic acid, 2α-hydroxy-
ursolic acid and asiatic acid, β-sitosterol 3-O-β-D-gluco-
pyranoside, glycerol 1,2-dilinolenyl-3-O-β-D-galactopyran-
oside, and glycerol 1,2-dilinolenyl-3-O-(4,6-O-isopropyli-
dene)-β-D-galactopyranoside. On the other hand, ethyl ace-
tate soluble part of AMMMFw contains a host of compo-
unds, namely, ellagic acid and 6 ﬂavonoids, namely,
quercetin, kaempferol, kaempferol 3-O-α-Lrhamnopyrano-
side, kaempferol 3-O-β-D-glucopyranoside, kaempferol 3-
O-β-D-galactopyranoside, and kaempferol 3-O-(2  ,6  -di-
O-E-p-coumaryl)-β-D-galactopyranoside [53, 54]. Loh´ ezic-
Le D´ ev´ ehat et al. [32] have reported the presence of ﬂavo-
noidsandhydrolysabletanninsintheaerialpartsofM.mala-
bathricum following the preliminary phytochemical screen-
ing.
In addition, Dinda and Saha [59]a n dY e o he ta l .[ 60]
have also reported on the presence and total leaf amino acid
compositions of M. malabathricum. The leaf of M. mala-
bathricum was found to contain all important amino acids,
n a m e l y ,A s p ,T h r ,S e r ,G l u ,P r o ,G l y ,A l a ,V a l ,M e t ,l i e ,L e u ,
Tyr, Phe, His, Lys, Trp, and Arg with their respective percent-
age of total amino acids of 11.5, 5.5, 5.1, 13.5, 6.2, 5.4, 6.4,
4.9, 2.3, 3.6, 9.9, 5.2, 6.2, 2.3, 6.9, 0.1, 4.9, and 4.24.Evidence-Based Complementary and Alternative Medicine 29
4.PharmacologicalActivities
Various parts of M. malabathricum have been claimed to
possess medicinal values, which is supported particularly
by the Malay and Indian traditional uses of the plants in
the treatment of a number of diseases as described earlier.
Scientiﬁcally, M. malabathricum, prepared as extracts using
diﬀerent types of solvents and tested using a range of in vitro
and in vivo test models, demonstrated various pharmaco-
logical potentials that required in-depth studies (Table 4).
The plant, regardless of the parts used, has been shown to
exert antibacterial, antiviral, antiparasitic, antioxidant, cyto-
toxicity, anticoagulant, platelet-activating factor inhibitory,
wound healing, antiulcer, antidiarrheal, antivenom, anti-in-
ﬂammatory, antinociceptive, and antipyretic activities at dif-
ferent doses/concentrations. The following subchapters will
discuss in detail those scientiﬁc ﬁndings related to pharma-
cological properties of M. malabathricum.
4.1. Acute Toxicity Study. Sunilson et al. [61]h a v ed e t e r -
mined the acute toxicity LD50 level of water extract of M.
malabathricum leaves (WMML) collected in the State of
Selangor,Malaysia.Theextract,inthedosesof62.5,125,250,
500, 1000, and 2000mg/kg, was administered orally in mice.
Theauthorsrecordedgeneralsignsandsymptomsoftoxicity,
intake of food and water, and mortality for 48h. The acute
toxicity study showed that the WMML administered up to
2000mg/kg dose to the mice showed neither mortality nor
any visible clinical signs of general weakness in the animals.
This indicates that the WMML is safe for consumption even
at the highest dosage (2000mg/kg) tested.
4.2. Antibacterial Activity. Grosvenor et al. [62] studied the
antimicrobial property of 70% methanol extract of com-
bined M. malabathricum leaf, stem, and ﬂower (MMMClsf),
collected from the Riau province, Sumatra, Indonesia,
against Escherichia coli, Staphylococcus aureus, Saccharomyces
cerevisiae,a n dFusarium oxysporum using the agar diﬀusion
assay. The extract was eﬀective only against S. aureus, S. cere-
visiae,a n dF. oxysporum. Standard antimicrobial references
used were 1mg/mL chloramphenicol, 1mg/mL tetracycline,
and 10000 units/mL nystatin suspensions. The chloramphe-
nicolandtetracyclineexertedantimicrobialactivityagainstS.
aureus and E. coli, while nystatin suspension exhibited anti-
microbial activity against S. cerevisiae and F. oxysporum.
Wiart et al. [63] studied the antibacterial and antifungal
properties of MMML, collected from Kuala Kangsar in the
State of Perak, Malaysia, against Bacillus cereus, B. subtilis,
Escherichia coli, Pseudomonas aeruginosa and Candida albi-
cans using the disc diﬀusion method. Standard antibiotics
used were 10μgg e n t a m y c i na n d2 0μg nystatin for antibac-
terial and antifungal comparison, respectively. The 1000μg
MMML exerted poor antimicrobial activity with zone of
growth inhibition recorded at 7mm only against B. subtilis.
In comparison, gentamycin was eﬀective against all micro-
organisms tested, except C. albicans, with zone of inhibition
ranging between 14 and 20mm while nystatin was eﬀective
against C. albicans with zone of inhibition recorded at
11mm.
Thatoi et al. [14] reported the antimicrobial activity
of the aqueous extract of diﬀerent parts of M. malabath-
ricum (e.g., AMML, stem (AMMS), bark (AMMBk), bulb
(AMMBb), fruit (AMMFr), and root (AMMR)), collected
from Simlipal Biosphere Reserve, Orissa, India, against a
panel of Gram-positive and Gram-negative human patho-
genic bacteria (e.g., Staphylococcus aureus MTCC 1144, B.
licheniformis MTCC 7425, B. brevis MTCC 7404, B. subtilis
MTCC7164,S.epidermidisMTCC3615,Streptococcusaureus
(lab isolate), P. aeruginosa MTCC 1034, E. coli MTCC 1089,
Vibrio cholerae (labisolate),andShigellaﬂexneri(labisolate))
and a fungal (e.g., C. krusei (lab isolate)). All extracts, in the
volume of 200μL and in the concentration of 200mg/mL
each,weretestedusingtheagarcupmethod.Fromtheresults
obtained, AMML was considered to have an outstanding
antimicrobial activity as indicated by the inhibition zones
produced that are more than 20mm. The AMML was eﬀec-
tive against B. brevis, V. cholerae, C. krusei,a n dB. subtilis,
while the AMMBk was eﬀective against S. aureus, B. brevis,
and V. cholerae.
Johnny et al. [64] reported the antifungal activity of
MMML, AcMML, and chloroform (CMML) extract of M.
malabathricum leaves collected from Sarikei in the State of
Sarawak, Malaysia, against Colletotrichum gloeosporioides,a
plant pathogenic fungus isolated from mango. The antifun-
gal activity was tested using agar-disc dilution assay followed
by determination of minimum inhibition concentration
(MIC) and the rate of sporulation assay. Benomyl was used
as positive control. M. malabathricum extracts showed 40–
55% antifungal activity against C. gloeosporioides at varying
concentrations. The MMML exhibited antifungal activity
of 53.09 ± 0.75mm at 10.00μg/mL, 48.85 ± 0.85mm at
1.00μg/mL, 44.94 ± 0.66mm at 0.10μg/mL, and 44.12 ±
0.45mm at 0.01μg/mL against C. gloeosporioides, while the
CMML exhibited antifungal activity of 49.45 ± 0.32mm at
10.00μg/mL,46.50±0.84mmat1.00μg/mL,42.55±0.71mm
at 0.10μg/mL, and 41.33 ± 0.51mm at 0.01μg/mL against
C. gloeosporioides. On the other hand, the AcMML exhibited
antifungalactivityof48.54±0.41mmat10.00μg/mL,43.74±
1.11mm at 1.00μg/mL, 39.43 ± 0.96mm at 0.10μg/mL, and
37.75 ± 0.56mm at 0.01μg/mL against C. gloeosporioides.
The MIC value recorded for the extracts was 20.00μg/mL. In
the next studies to determine the inhibition of sporulation
of C. gloeosporioides, the MMML exerted inhibition of spo-
rulation (×105)o f2 .33 ± 0.04 at 10.00μg/mL, 2.29 ± 0.03
at 1.00μg/mL, 2.20 ± 0.03 at 0.10μg/mL, and 1.98 ± 0.03
at 0.01μg/mL against C. gloeosporioides, while the CMML
exerted inhibition of sporulation (×105)o f2 .27 ± 0.04
at 10.00μg/mL, 1.89 ± 0.03 at 1.00μg/mL, 1.80 ± 0.03 at
0.10μg/mL, and 1.77 ± 0.03 at 0.01μg/mL against C. gloe-
osporioides. On the other hand, the AcMML exerted inhibi-
tion of sporulation (×105)o f2 .24 ± 0.04 at 10.00μg/mL at
10.00μg/mL against 1.76 ± 0.03 at 1.00μg/mL, 1.75 ± 0.02
at 0.10μg/mL, and 1.76 ± 0.03 at 0.01μg/mL against C. gloe-
osporioides.
Maji et al. [65] examined the antimicrobial eﬃciency of
WMML, AcMML, and benzene (BMML) extracts of M. mal-
abathricum leaves collected from Gurguripal forest, Midna-
pur, West Bengal, India, against seven human pathogens30 Evidence-Based Complementary and Alternative Medicine
T
a
b
l
e
4
:
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
p
r
o
p
e
r
t
i
e
s
o
f
M
.
m
a
l
a
b
a
t
h
r
i
c
u
m
a
c
c
o
r
d
i
n
g
t
o
i
t
s
p
a
r
t
.
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
c
t
i
v
i
t
y
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
s
s
a
y
u
s
e
d
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
D
o
s
e
(
m
g
/
k
g
)
o
r
c
o
n
c
e
n
t
r
a
t
i
o
n
(
m
g
/
m
L
)
O
b
s
e
r
v
a
t
i
o
n
s
R
e
f
e
r
e
n
c
e
(
s
)
A
c
u
t
e
t
o
x
i
c
i
t
y
S
i
g
n
s
o
f
t
o
x
i
c
i
t
y
w
e
r
e
o
b
s
e
r
v
e
d
f
o
r
4
8
h
i
n
o
r
a
l
l
y
f
e
d
m
i
c
e
L
e
a
v
e
s
W
a
t
e
r
e
x
t
r
a
c
t
6
2
.
5
,
1
2
5
,
2
5
0
,
5
0
0
,
1
0
0
0
,
a
n
d
2
0
0
0
m
g
/
k
g
;
g
i
v
e
n
o
r
a
l
l
y
T
h
e
W
M
M
L
g
i
v
e
n
t
o
m
i
c
e
u
p
t
o
t
h
e
d
o
s
e
o
f
2
0
0
0
m
g
/
k
g
s
h
o
w
e
d
n
e
i
t
h
e
r
m
o
r
t
a
l
i
t
y
n
o
r
a
n
y
v
i
s
i
b
l
e
c
l
i
n
i
c
a
l
s
i
g
n
s
o
f
g
e
n
e
r
a
l
w
e
a
k
n
e
s
s
i
n
t
h
e
a
n
i
m
a
l
s
S
u
n
i
l
s
o
n
e
t
a
l
.
[
6
1
]
A
n
t
i
b
a
c
t
e
r
i
a
l
A
g
a
r
d
i
ﬀ
u
s
i
o
n
a
s
s
a
y
C
o
m
b
i
n
a
t
i
o
n
o
f
l
e
a
f
,
s
t
e
m
,
a
n
d
ﬂ
o
w
e
r
7
0
%
m
e
t
h
a
n
o
l
e
x
t
r
a
c
t
C
o
n
c
e
n
t
r
a
t
i
o
n
u
s
e
d
w
a
s
n
o
t
c
l
e
a
r
l
y
d
e
s
c
r
i
b
e
d
2
0
μ
L
e
x
t
r
a
c
t
w
a
s
p
o
u
r
e
d
i
n
t
o
w
e
l
l
s
T
h
e
A
M
M
M
l
s
f
w
a
s
e
ﬀ
e
c
t
i
v
e
o
n
l
y
a
g
a
i
n
s
t
S
.
a
u
r
e
u
s
,
S
.
c
e
r
e
v
i
s
i
a
e
,
a
n
d
F
.
o
x
y
s
p
o
r
u
m
b
u
t
n
o
t
E
.
c
o
l
i
.
G
r
o
s
v
e
n
o
r
e
t
a
l
.
[
8
]
D
i
s
c
d
i
ﬀ
u
s
i
o
n
a
s
s
a
y
L
e
a
v
e
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
O
n
l
y
1
.
0
m
g
/
m
L
e
x
t
r
a
c
t
u
s
e
d
T
h
e
M
M
M
L
e
x
h
i
b
i
t
e
d
p
o
o
r
a
n
t
i
m
i
c
r
o
b
i
a
l
a
c
t
i
v
i
t
y
o
n
l
y
a
g
a
i
n
s
t
B
.
s
u
b
t
i
l
i
s
,
b
u
t
n
o
t
B
.
c
e
r
e
u
s
,
E
.
c
o
l
i
,
P
.
a
e
r
u
g
i
n
o
s
a
,
a
n
d
C
.
a
l
b
i
c
a
n
s
.
W
i
a
r
t
e
t
a
l
.
[
6
3
]
A
g
a
r
c
u
p
a
s
s
a
y
D
i
ﬀ
e
r
e
n
t
p
a
r
t
(
l
e
a
f
,
s
t
e
m
,
b
a
r
k
,
b
u
l
b
,
f
r
u
i
t
a
n
d
r
o
o
t
)
A
q
u
e
o
u
s
e
x
t
r
a
c
t
1
0
0
μ
L
o
f
2
0
0
m
g
/
m
L
e
x
t
r
a
c
t
s
w
a
s
p
o
u
r
e
d
i
n
t
o
w
e
l
l
s
A
l
l
e
x
t
r
a
c
t
s
e
x
e
r
t
e
d
a
n
t
i
m
i
c
r
o
b
i
a
l
a
c
t
i
v
i
t
y
T
h
e
A
M
M
L
e
x
h
i
b
i
t
e
d
t
h
e
m
o
s
t
e
ﬀ
e
c
t
i
v
e
a
n
t
i
m
i
c
r
o
b
i
a
l
a
c
t
i
v
i
t
y
.
T
h
e
A
M
M
L
w
a
s
e
ﬀ
e
c
t
i
v
e
a
g
a
i
n
s
t
B
.
b
r
e
v
i
s
,
V
.
c
h
o
l
e
r
a
e
,
C
.
k
r
u
s
e
i
,
a
n
d
B
.
s
u
b
t
i
l
i
s
,
w
h
i
l
e
t
h
e
A
M
M
B
k
w
a
s
e
ﬀ
e
c
t
i
v
e
a
g
a
i
n
s
t
S
.
a
u
r
e
u
s
,
B
.
b
r
e
v
i
s
,
a
n
d
V
.
c
h
o
l
e
r
a
e
.
T
h
a
t
o
i
e
t
a
l
.
[
1
4
]
A
g
a
r
-
d
i
s
c
d
i
l
u
t
i
o
n
a
s
s
a
y
L
e
a
v
e
s
M
e
t
h
a
n
o
l
,
c
h
l
o
r
o
f
o
r
m
,
a
n
d
a
c
e
t
o
n
e
e
x
t
r
a
c
t
s
0
.
0
1
,
0
.
1
0
,
1
.
0
0
,
a
n
d
1
0
.
0
0
μ
g
/
m
L
.
1
m
L
o
f
e
a
c
h
e
x
t
r
a
c
t
w
a
s
m
i
x
e
d
w
i
t
h
1
9
m
L
o
f
m
e
d
i
a
a
n
d
p
o
u
r
e
d
i
n
t
o
p
e
t
r
i
d
i
s
h
e
s
.
M
y
c
e
l
i
a
l
d
i
s
c
s
w
e
r
e
i
n
o
c
u
l
a
t
e
d
a
t
t
h
e
c
e
n
t
e
r
o
f
a
g
a
r
m
e
d
i
u
m
T
h
e
e
x
t
r
a
c
t
s
s
h
o
w
e
d
a
n
t
i
f
u
n
g
a
l
a
c
t
i
v
i
t
y
a
g
a
i
n
s
t
C
.
g
l
o
e
o
s
p
o
r
i
o
i
d
e
s
.
T
h
e
M
I
C
v
a
l
u
e
o
b
t
a
i
n
e
d
f
o
r
a
l
l
e
x
t
r
a
c
t
s
w
a
s
2
0
.
0
0
μ
g
/
m
L
.
T
h
e
e
x
t
r
a
c
t
s
a
l
s
o
i
n
h
i
b
i
t
e
d
t
h
e
s
p
o
r
u
l
a
t
i
o
n
o
f
t
e
s
t
e
d
f
u
n
g
u
s
J
o
h
n
n
y
e
t
a
l
.
[
6
4
]Evidence-Based Complementary and Alternative Medicine 31
T
a
b
l
e
4
:
C
o
n
t
i
n
u
e
d
.
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
c
t
i
v
i
t
y
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
s
s
a
y
u
s
e
d
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
D
o
s
e
(
m
g
/
k
g
)
o
r
c
o
n
c
e
n
t
r
a
t
i
o
n
(
m
g
/
m
L
)
O
b
s
e
r
v
a
t
i
o
n
s
R
e
f
e
r
e
n
c
e
(
s
)
A
g
a
r
w
e
l
l
d
i
ﬀ
u
s
i
o
n
a
s
s
a
y
L
e
a
v
e
s
W
a
t
e
r
,
b
e
n
z
e
n
e
,
a
n
d
a
c
e
t
o
n
e
e
x
t
r
a
c
t
s
5
0
μ
L
o
f
1
.
0
m
g
/
m
L
e
x
t
r
a
c
t
p
e
r
w
e
l
l
A
l
l
e
x
t
r
a
c
t
s
p
o
s
s
e
s
s
e
d
m
o
d
e
r
a
t
e
a
n
t
i
m
i
c
r
o
b
i
a
l
a
c
t
i
v
i
t
y
a
g
a
i
n
s
t
E
.
c
o
l
i
(
M
D
R
)
,
S
.
a
u
r
e
u
s
(
M
D
R
)
,
K
.
p
n
e
u
m
o
n
i
a
e
,
B
.
c
e
r
e
u
s
,
V
.
c
h
o
l
e
r
a
,
a
n
d
C
.
a
l
b
i
c
a
n
s
.
T
h
e
M
I
C
v
a
l
u
e
f
o
r
a
l
l
e
x
t
r
a
c
t
s
r
a
n
g
e
d
b
e
t
w
e
e
n
0
.
6
5
a
n
d
0
.
8
0
m
g
/
m
L
,
w
h
i
l
e
t
h
e
M
B
C
v
a
l
u
e
w
a
s
0
.
9
0
m
g
/
m
L
a
g
a
i
n
s
t
V
.
c
h
o
l
e
r
a
.
T
h
e
M
I
C
v
a
l
u
e
f
o
r
W
M
M
L
a
n
d
A
c
M
M
L
w
a
s
0
.
8
0
a
n
d
0
.
7
9
m
g
/
m
L
,
r
e
s
p
e
c
t
i
v
e
l
y
,
w
h
i
l
e
t
h
e
M
B
C
v
a
l
u
e
w
a
s
1
.
0
0
m
g
/
m
L
a
g
a
i
n
s
t
S
.
a
u
r
e
u
s
(
M
D
R
)
.
O
n
l
y
A
c
M
M
L
p
r
o
d
u
c
e
d
t
h
e
M
I
C
v
a
l
u
e
r
a
n
g
i
n
g
b
e
t
w
e
e
n
0
.
6
2
a
n
d
0
.
8
0
m
g
/
m
L
a
n
d
t
h
e
M
B
C
v
a
l
u
e
r
a
n
g
i
n
g
b
e
t
w
e
e
n
0
.
7
0
a
n
d
0
.
9
0
m
g
/
m
L
a
g
a
i
n
s
t
E
.
c
o
l
i
(
M
D
R
)
,
K
.
p
n
e
u
m
o
n
i
a
e
,
C
.
a
l
b
i
c
a
n
s
,
a
n
d
B
.
c
e
r
e
u
s
.
M
a
j
i
e
t
a
l
.
[
6
5
]
A
g
a
r
w
e
l
l
d
i
ﬀ
u
s
i
o
n
a
s
s
a
y
L
e
a
v
e
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
T
h
e
e
x
t
r
a
c
t
w
a
s
t
e
s
t
e
d
i
n
t
h
e
c
o
n
c
e
n
t
r
a
t
i
o
n
s
o
f
0
.
5
,
1
.
0
,
2
.
0
,
3
.
0
,
4
.
0
,
6
.
0
,
8
.
0
,
a
n
d
1
6
.
0
m
g
/
m
L
T
h
e
M
M
M
L
e
x
h
i
b
i
t
e
d
a
n
t
i
b
a
c
t
e
r
i
a
l
a
c
t
i
v
i
t
y
a
t
t
h
e
M
I
C
v
a
l
u
e
o
f
3
.
0
m
g
/
m
L
f
o
r
A
,
B
,
a
n
d
D
a
n
d
7
.
0
m
g
/
m
L
f
o
r
C
c
l
i
n
i
c
a
l
s
t
r
a
i
n
s
o
f
S
.
a
u
r
e
u
s
,
r
e
s
p
e
c
t
i
v
e
l
y
.
T
h
e
M
I
C
v
a
l
u
e
r
e
c
o
r
d
e
d
f
o
r
t
h
e
t
h
r
e
e
c
l
i
n
i
c
a
l
i
s
o
l
a
t
e
s
o
f
P
.
a
e
r
u
g
i
n
o
s
a
(
A
,
B
,
a
n
d
C
)
w
a
s
8
.
0
m
g
/
m
L
.
N
A
F
r
u
i
t
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
N
A
T
h
e
M
M
M
F
r
d
e
m
o
n
s
t
r
a
t
e
d
a
n
t
i
b
a
c
t
e
r
i
a
l
a
c
t
i
v
i
t
y
a
g
a
i
n
s
t
B
.
s
u
b
t
i
l
i
s
,
S
.
a
u
r
e
u
s
,
E
.
c
o
l
i
,
a
n
d
P
.
a
e
r
u
g
i
n
o
s
a
w
i
t
h
M
I
C
v
a
l
u
e
r
a
n
g
i
n
g
b
e
t
w
e
e
n
6
2
.
5
a
n
d
1
2
5
.
0
μ
g
/
m
L
K
o
a
y
[
2
3
]32 Evidence-Based Complementary and Alternative Medicine
T
a
b
l
e
4
:
C
o
n
t
i
n
u
e
d
.
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
c
t
i
v
i
t
y
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
s
s
a
y
u
s
e
d
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
D
o
s
e
(
m
g
/
k
g
)
o
r
c
o
n
c
e
n
t
r
a
t
i
o
n
(
m
g
/
m
L
)
O
b
s
e
r
v
a
t
i
o
n
s
R
e
f
e
r
e
n
c
e
(
s
)
A
n
t
i
v
i
r
a
l
I
n
v
i
t
r
o
c
y
t
o
p
a
t
h
i
c
e
ﬀ
e
c
t
i
n
h
i
b
i
t
i
o
n
a
s
s
a
y
A
e
r
i
a
l
p
a
r
t
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
N
o
t
a
p
p
r
o
p
r
i
a
t
e
l
y
d
e
s
c
r
i
b
e
d
i
n
t
e
x
t
T
h
e
M
M
M
A
p
s
h
o
w
e
d
m
o
d
e
r
a
t
e
a
n
t
i
-
H
S
V
-
1
a
c
t
i
v
i
t
y
w
i
t
h
r
e
m
a
r
k
a
b
l
e
a
c
t
i
v
i
t
y
a
g
a
i
n
s
t
P
o
l
i
o
v
i
r
u
s
.
T
h
e
C
C
5
0
v
a
l
u
e
o
f
M
M
M
A
p
a
g
a
i
n
s
t
H
S
V
-
1
a
n
d
P
o
l
i
o
v
i
r
u
s
w
a
s
>
1
0
0
0
μ
g
/
m
L
o
r
e
q
u
a
l
t
o
1
0
0
0
μ
g
/
m
L
,
r
e
s
p
e
c
t
i
v
e
l
y
.
T
h
e
E
C
5
0
v
a
l
u
e
f
o
r
M
M
M
A
p
a
g
a
i
n
s
t
H
S
V
-
1
v
i
r
u
s
a
t
2
0
T
C
I
D
5
0
a
n
d
2
0
0
T
C
I
D
5
0
w
a
s
1
9
2
a
n
d
7
0
6
μ
g
/
m
L
.
T
h
e
E
C
5
0
v
a
l
u
e
f
o
r
M
M
M
A
p
a
g
a
i
n
s
t
P
o
l
i
o
v
i
r
u
s
a
t
2
0
T
C
I
D
5
0
a
n
d
2
0
0
T
C
I
D
5
0
w
a
s
1
1
1
a
n
d
2
2
5
μ
g
/
m
L
,
r
e
s
p
e
c
t
i
v
e
l
y
.
L
o
h
´
e
z
i
c
-
L
e
D
´
e
v
´
e
h
a
t
e
t
a
l
.
[
3
2
]
T
h
r
e
e
i
n
v
i
t
r
o
m
e
t
h
o
d
s
o
f
t
r
e
a
t
m
e
n
t
:
(
i
)
c
e
l
l
s
(
C
)
w
e
r
e
i
n
o
c
u
l
a
t
e
d
w
i
t
h
v
i
r
u
s
(
V
)
1
h
o
u
r
b
e
f
o
r
e
t
r
e
a
t
m
e
n
t
w
i
t
h
e
x
t
r
a
c
t
(
E
)
,
t
h
a
t
i
s
(
C
+
V
)
+
E
;
(
i
i
)
v
i
r
u
s
w
a
s
i
n
o
c
u
l
a
t
e
d
t
o
c
e
l
l
s
o
n
e
d
a
y
a
f
t
e
r
t
r
e
a
t
m
e
n
t
w
i
t
h
e
x
t
r
a
c
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c
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c
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c
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c
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b
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t
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.
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.
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L
e
x
e
r
t
e
d
a
n
t
i
v
i
r
a
l
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v
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t
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ﬀ
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o
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c
t
i
o
n
a
g
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n
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h
e
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M
M
L
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ﬀ
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t
i
v
e
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y
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n
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c
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l
l
d
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t
h
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l
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c
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l
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r
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d
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c
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c
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v
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l
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c
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d
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ﬀ
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i
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h
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d
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i
t
i
c
I
n
v
i
v
o
c
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c
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c
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c
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c
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p
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A
l
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n
e
t
a
l
.
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c
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f
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i
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p
f
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c
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i
d
e
.
T
h
e
I
C
5
0
v
a
l
u
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p
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c
o
p
y
r
a
n
o
s
i
d
e
r
a
n
g
i
n
g
b
e
t
w
e
e
n
6
.
5
9
–
3
5
.
8
μ
g
/
m
L
.
S
u
s
a
n
t
i
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d
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c
t
h
i
o
c
y
a
n
a
t
e
(
F
T
C
)
m
e
t
h
o
d
;
(
i
i
)
2
,
2
-
d
i
p
h
e
n
y
l
-
1
-
p
i
c
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p
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c
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p
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c
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c
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c
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c
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i
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0
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7
.
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/
m
L
i
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h
e
D
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P
H
a
s
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a
e
m
p
f
e
r
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d
i
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p
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r
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o
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c
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i
d
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a
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f
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O
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c
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c
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c
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v
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c
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.
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p
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c
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c
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i
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c
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b
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.
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p
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c
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c
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c
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c
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c
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e
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r
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p
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b
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c
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c
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c
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i
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h
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c
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w
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/
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c
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c
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,
6
 
 
-
d
i
-
O
-
p
-
t
r
a
n
s
-
c
o
u
m
a
r
o
y
l
)
-
β
-
g
l
u
c
o
p
y
r
a
n
o
s
i
d
e
w
a
s
m
o
r
e
e
ﬀ
e
c
t
i
v
e
t
h
a
n
t
a
m
o
x
i
f
e
n
S
u
s
a
n
t
i
e
t
a
l
.
[
2
2
]
I
n
v
i
t
r
o
M
T
T
a
s
s
a
y
a
g
a
i
n
s
t
V
e
r
o
(
A
f
r
i
c
a
n
g
r
e
e
n
m
o
n
k
e
y
,
C
e
r
c
o
p
i
t
h
e
u
s
a
e
t
h
i
o
p
s
k
i
d
n
e
y
c
e
l
l
s
)
a
n
d
L
9
2
9
(
m
o
u
s
e
ﬁ
b
r
o
b
l
a
s
t
)
c
e
l
l
s
l
i
n
e
s
L
e
a
v
e
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
C
o
n
c
e
n
t
r
a
t
i
o
n
u
s
e
d
w
e
r
e
n
o
t
c
l
e
a
r
l
y
e
x
p
l
a
i
n
e
d
D
i
ﬀ
e
r
e
n
t
c
o
n
c
e
n
t
r
a
t
i
o
n
s
o
f
e
x
t
r
a
c
t
w
e
r
e
u
s
e
d
a
n
d
p
r
e
p
a
r
e
d
u
s
i
n
g
d
o
u
b
l
i
n
g
d
i
l
u
t
i
o
n
s
f
r
o
m
i
n
i
t
i
a
l
s
t
o
c
k
c
o
n
c
e
n
t
r
a
t
i
o
n
o
f
1
0
0
0
μ
g
/
m
L
T
h
e
M
M
M
L
w
a
s
n
o
t
c
y
t
o
t
o
x
i
c
t
o
b
o
t
h
c
e
l
l
s
w
i
t
h
L
C
5
0
v
a
l
u
e
s
o
f
7
5
0
μ
g
/
m
L
a
n
d
>
1
0
0
0
μ
g
/
m
L
,
r
e
s
p
e
c
t
i
v
e
l
y
N
a
z
l
i
n
a
e
t
a
l
.
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T
a
b
l
e
4
:
C
o
n
t
i
n
u
e
d
.
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
c
t
i
v
i
t
y
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
s
s
a
y
u
s
e
d
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
D
o
s
e
(
m
g
/
k
g
)
o
r
c
o
n
c
e
n
t
r
a
t
i
o
n
(
m
g
/
m
L
)
O
b
s
e
r
v
a
t
i
o
n
s
R
e
f
e
r
e
n
c
e
(
s
)
A
n
t
i
c
o
a
g
u
l
a
n
t
I
n
v
i
t
r
o
a
s
s
a
y
u
s
i
n
g
t
h
e
b
l
o
o
d
s
a
m
p
l
e
s
d
r
a
w
n
f
r
o
m
h
e
a
l
t
h
y
v
o
l
u
n
t
e
e
r
d
o
n
o
r
s
(
n
=
3
6
)
o
f
b
o
t
h
g
e
n
d
e
r
s
(
1
8
–
5
0
y
e
a
r
s
o
l
d
)
T
h
e
c
o
a
g
u
l
a
t
i
o
n
p
a
r
a
m
e
t
e
r
s
m
e
a
s
u
r
e
d
u
s
i
n
g
S
T
A
C
o
m
p
a
c
t
c
o
a
g
u
l
a
t
i
o
n
a
n
a
l
y
z
e
r
w
e
r
e
t
h
e
a
c
t
i
v
a
t
e
d
p
a
r
t
i
a
l
t
h
r
o
m
b
o
p
l
a
s
t
i
n
t
i
m
e
(
a
P
T
T
)
,
p
r
o
t
h
r
o
m
b
i
n
t
i
m
e
(
P
T
)
,
a
n
d
t
h
r
o
m
b
i
n
t
i
m
e
(
T
T
)
w
i
t
h
c
u
t
-
o
ﬀ
t
i
m
e
o
f
1
8
0
s
B
l
o
o
d
-
c
l
o
t
-
b
a
s
e
d
a
s
s
a
y
w
i
t
h
c
u
t
-
o
ﬀ
t
i
m
e
o
f
3
0
0
s
L
e
a
v
e
s
H
o
t
w
a
t
e
r
e
x
t
r
a
c
t
,
c
o
l
d
w
a
t
e
r
e
x
t
r
a
c
t
,
a
n
d
m
e
t
h
a
n
o
l
e
x
t
r
a
c
t
C
o
n
c
e
n
t
r
a
t
i
o
n
s
r
a
n
g
i
n
g
b
e
t
w
e
e
n
1
0
0
a
n
d
1
0
0
0
μ
g
/
m
L
T
h
e
1
0
0
0
μ
g
/
m
L
h
o
t
-
W
M
M
L
p
r
o
l
o
n
g
e
d
a
P
T
T
,
P
T
a
n
d
T
T
i
n
p
l
a
s
m
a
b
u
t
d
i
d
n
o
t
c
l
o
t
t
h
e
p
l
a
s
m
a
s
a
m
p
l
e
s
.
T
h
e
c
o
l
d
-
W
M
M
L
a
n
d
M
M
M
L
a
l
s
o
p
r
o
l
o
n
g
e
d
a
P
T
T
,
P
T
,
b
u
t
b
o
t
h
e
x
t
r
a
c
t
s
d
i
d
n
o
t
a
ﬀ
e
c
t
t
h
e
T
T
.
1
0
0
t
o
1
0
0
0
μ
g
/
m
L
h
o
t
-
W
M
M
L
p
r
o
l
o
n
g
e
d
a
P
T
T
i
n
a
c
o
n
c
e
n
t
r
a
t
i
o
n
-
d
e
p
e
n
d
e
n
t
m
a
n
n
e
r
w
i
t
h
a
n
t
i
c
o
a
g
u
l
a
n
t
a
c
t
i
v
i
t
y
r
e
c
o
r
d
e
d
a
t
t
h
e
c
o
n
c
e
n
t
r
a
t
i
o
n
b
e
y
o
n
d
4
0
0
μ
g
/
m
L
.
T
h
e
h
o
t
-
W
M
M
L
d
i
d
n
o
t
e
x
h
i
b
i
t
b
l
o
o
d
c
l
o
t
t
i
n
g
e
ﬀ
e
c
t
a
s
i
n
d
i
c
a
t
e
d
b
y
p
r
o
l
o
n
g
e
d
a
P
T
T
b
e
y
o
n
d
3
0
0
s
a
t
9
0
0
a
n
d
1
0
0
0
μ
g
/
m
L
M
a
n
i
c
a
m
e
t
a
l
.
[
6
8
]
P
l
a
t
e
l
e
t
-
a
c
t
i
v
a
t
i
n
g
f
a
c
t
o
r
(
P
A
F
)
i
n
h
i
b
i
t
o
r
I
n
v
i
t
r
o
P
A
F
b
i
n
d
i
n
g
t
o
r
a
b
b
i
t
p
l
a
t
e
l
e
t
s
a
s
s
a
y
L
e
a
v
e
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
2
0
0
,
1
0
0
,
5
0
,
2
0
a
n
d
1
0
μ
g
/
m
L
T
h
e
M
M
M
L
p
r
o
d
u
c
e
d
<
1
0
%
i
n
h
i
b
i
t
o
r
y
e
ﬀ
e
c
t
a
g
a
i
n
s
t
P
A
F
.
J
a
n
t
a
n
e
t
a
l
.
[
6
9
]
I
n
v
i
t
r
o
P
A
F
b
i
n
d
i
n
g
t
o
r
a
b
b
i
t
p
l
a
t
e
l
e
t
s
a
s
s
a
y
L
e
a
v
e
s
α
-
A
m
y
r
i
n
,
b
e
t
u
l
i
n
i
c
a
c
i
d
,
q
u
e
r
c
e
t
i
n
a
n
d
q
u
e
r
c
i
t
r
i
n
S
e
r
i
a
l
c
o
n
c
e
n
t
r
a
t
i
o
n
d
i
l
u
t
i
o
n
r
a
n
g
e
o
f
1
8
.
2
–
1
.
8
μ
g
/
m
L
(
1
8
.
2
,
9
.
1
,
4
.
5
,
a
n
d
1
.
8
μ
g
/
m
L
)
A
t
1
8
.
2
μ
g
/
m
L
,
a
l
l
c
o
m
p
o
u
n
d
s
e
x
e
r
t
e
d
i
n
h
i
b
i
t
o
r
y
a
c
t
i
o
n
r
a
n
g
i
n
g
b
e
t
w
e
e
n
4
0
t
o
7
0
%
w
i
t
h
e
ﬀ
e
c
t
i
v
e
n
e
s
s
s
e
e
n
i
n
t
h
e
s
e
q
u
e
n
c
e
o
f
α
-
a
m
y
r
i
n
,
b
e
t
u
l
i
n
i
c
a
c
i
d
,
q
u
e
r
c
e
t
i
n
,
a
n
d
q
u
e
r
c
i
t
r
i
n
.
T
h
e
I
C
5
0
v
a
l
u
e
f
o
r
α
-
a
m
y
r
i
n
,
b
e
t
u
l
i
n
i
c
a
c
i
d
,
q
u
e
r
c
e
t
i
n
,
a
n
d
q
u
e
r
c
i
t
r
i
n
,
r
a
n
g
e
d
b
e
t
w
e
e
n
2
0
.
0
a
n
d
4
5
.
4
μ
M
M
a
z
u
r
a
e
t
a
l
.
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T
a
b
l
e
4
:
C
o
n
t
i
n
u
e
d
.
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
c
t
i
v
i
t
y
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
s
s
a
y
u
s
e
d
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
D
o
s
e
(
m
g
/
k
g
)
o
r
c
o
n
c
e
n
t
r
a
t
i
o
n
(
m
g
/
m
L
)
O
b
s
e
r
v
a
t
i
o
n
s
R
e
f
e
r
e
n
c
e
(
s
)
W
o
u
n
d
h
e
a
l
i
n
g
T
w
o
t
y
p
e
s
o
f
i
n
v
i
v
o
w
o
u
n
d
m
o
d
e
l
s
i
n
r
a
t
s
:
(
i
)
t
h
e
e
x
c
i
s
i
o
n
w
o
u
n
d
m
o
d
e
l
;
(
i
i
)
t
h
e
i
n
c
i
s
i
o
n
w
o
u
n
d
m
o
d
e
l
L
e
a
v
e
s
M
e
t
h
a
n
o
l
e
x
t
r
a
c
t
i
n
t
h
e
f
o
r
m
o
f
o
i
n
t
m
e
n
t
T
h
e
e
x
t
r
a
c
t
w
a
s
p
r
e
p
a
r
e
d
a
s
5
%
o
i
n
t
m
e
n
t
;
a
p
p
l
i
e
d
t
o
p
i
c
a
l
l
y
I
n
t
h
e
e
x
c
i
s
i
o
n
w
o
u
n
d
m
o
d
e
l
:
t
h
e
M
M
M
L
e
x
h
i
b
i
t
e
d
a
w
o
u
n
d
h
e
a
l
i
n
g
a
c
t
i
v
i
t
y
b
y
i
n
c
r
e
a
s
i
n
g
w
o
u
n
d
c
o
n
t
r
a
c
t
i
n
g
a
b
i
l
i
t
y
,
w
o
u
n
d
c
l
o
s
u
r
e
t
i
m
e
,
t
e
n
s
i
l
e
s
t
r
e
n
g
t
h
,
a
n
d
r
e
g
e
n
e
r
a
t
i
o
n
o
f
t
i
s
s
u
e
s
a
t
t
h
e
w
o
u
n
d
s
i
t
e
;
t
h
e
t
i
m
e
t
o
w
o
u
n
d
c
l
o
s
u
r
e
o
f
t
h
e
n
i
t
r
o
f
u
r
a
z
o
n
e
-
a
n
d
t
h
e
M
M
M
L
-
t
r
e
a
t
e
d
g
r
o
u
p
s
w
a
s
s
a
m
e
(
1
8
±
2
d
a
y
s
)
.
I
n
t
h
e
i
n
c
i
s
i
o
n
w
o
u
n
d
s
t
u
d
i
e
s
:
t
h
e
M
M
M
L
o
i
n
t
m
e
n
t
i
n
c
r
e
a
s
e
d
t
h
e
t
e
n
s
i
l
e
s
t
r
e
n
g
t
h
o
f
t
h
e
1
0
-
d
a
y
-
o
l
d
w
o
u
n
d
;
t
h
e
M
M
M
L
o
i
n
t
m
e
n
t
a
l
s
o
e
n
h
a
n
c
e
d
o
r
i
g
i
n
a
l
t
i
s
s
u
e
r
e
g
e
n
e
r
a
t
i
o
n
o
f
t
h
e
s
k
i
n
w
o
u
n
d
s
w
i
t
h
l
e
s
s
ﬁ
b
r
o
s
i
s
f
o
r
m
a
t
i
o
n
S
u
n
i
l
s
o
n
e
t
a
l
.
[
6
6
]
A
n
t
i
u
l
c
e
r
I
n
v
i
v
o
e
t
h
a
n
o
l
-
i
n
d
u
c
e
d
g
a
s
t
r
i
c
m
u
c
o
s
a
l
i
n
j
u
r
i
e
s
i
n
r
a
t
s
L
e
a
v
e
s
A
q
u
e
o
u
s
e
x
t
r
a
c
t
2
5
0
a
n
d
5
0
0
m
g
/
k
g
;
g
i
v
e
n
o
r
a
l
l
y
M
a
c
r
o
s
c
o
p
i
c
a
l
l
y
,
t
h
e
A
M
M
L
r
e
d
u
c
e
d
t
h
e
f
o
r
m
a
t
i
o
n
o
f
g
a
s
t
r
i
c
m
u
c
o
s
a
l
i
n
j
u
r
i
e
s
i
n
a
d
o
s
e
-
d
e
p
e
n
d
e
n
t
m
a
n
n
e
r
.
M
i
c
r
o
s
c
o
p
i
c
a
l
l
y
,
t
h
e
5
0
0
m
g
/
k
g
A
M
M
L
p
r
o
v
i
d
e
d
t
h
e
b
e
s
t
p
r
o
t
e
c
t
i
o
n
t
o
t
h
e
g
a
s
t
r
i
c
m
u
c
o
s
a
i
n
r
a
t
s
a
g
a
i
n
s
t
e
t
h
a
n
o
l
-
i
n
d
u
c
e
d
g
a
s
t
r
i
c
u
l
c
e
r
s
H
u
s
s
a
i
n
e
t
a
l
.
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T
a
b
l
e
4
:
C
o
n
t
i
n
u
e
d
.
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
c
t
i
v
i
t
y
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
a
s
s
a
y
u
s
e
d
P
l
a
n
t
p
a
r
t
T
y
p
e
s
o
f
e
x
t
r
a
c
t
D
o
s
e
(
m
g
/
k
g
)
o
r
c
o
n
c
e
n
t
r
a
t
i
o
n
(
m
g
/
m
L
)
O
b
s
e
r
v
a
t
i
o
n
s
R
e
f
e
r
e
n
c
e
(
s
)
A
n
t
i
d
i
a
r
r
h
e
a
l
F
o
u
r
i
n
v
i
v
o
e
x
p
e
r
i
m
e
n
t
a
l
m
o
d
e
l
s
o
f
d
i
a
r
r
h
e
a
i
n
m
i
c
e
:
(
i
)
m
o
d
e
l
1
:
m
i
c
e
w
e
r
e
g
i
v
e
n
t
e
s
t
s
o
l
u
t
i
o
n
s
a
n
d
f
e
c
a
l
m
a
t
e
r
i
a
l
s
w
e
r
e
c
o
l
l
e
c
t
e
d
f
o
r
1
2
h
a
f
t
e
r
t
r
e
a
t
m
e
n
t
,
d
r
i
e
d
i
n
a
n
i
n
c
u
b
a
t
o
r
a
n
d
w
e
i
g
h
e
d
;
(
i
i
)
m
o
d
e
l
2
:
a
n
o
v
e
r
n
i
g
h
t
f
a
s
t
e
d
m
a
l
e
m
o
u
s
e
w
a
s
i
n
d
u
c
e
d
w
i
t
h
d
i
a
r
r
h
e
a
b
y
o
r
a
l
a
d
m
i
n
i
s
t
r
a
t
i
o
n
o
f
c
a
s
t
o
r
o
i
l
(
0
.
5
m
L
/
m
o
u
s
e
,
p
.
o
.
)
1
h
o
u
r
a
f
t
e
r
t
h
e
t
e
s
t
s
o
l
u
t
i
o
n
s
a
d
m
i
n
i
s
t
r
a
t
i
o
n
;
(
i
i
i
)
m
o
d
e
l
3
:
t
h
e
o
v
e
r
n
i
g
h
t
f
a
s
t
e
d
m
i
c
e
w
e
r
e
s
u
b
j
e
c
t
e
d
t
o
t
h
e
e
n
t
e
r
o
p
o
o
l
i
n
g
a
s
s
a
y
m
e
t
h
o
d
t
o
ﬁ
n
d
o
u
t
t
h
e
a
c
c
u
m
u
l
a
t
i
o
n
o
f
i
n
t
e
s
t
i
n
a
l
ﬂ
u
i
d
s
e
c
r
e
t
i
o
n
e
v
o
k
e
d
b
y
M
g
S
O
4
;
(
i
v
)
m
o
d
e
l
4
:
t
h
e
o
v
e
r
n
i
g
h
t
f
a
s
t
e
d
a
n
i
m
a
l
s
w
e
r
e
s
u
b
j
e
c
t
e
d
t
o
t
h
e
g
a
s
t
r
o
i
n
t
e
s
t
i
n
a
l
t
r
a
n
s
i
t
t
e
s
t
a
n
d
t
h
e
d
i
s
t
a
n
c
e
t
r
a
v
e
l
l
e
d
b
y
t
h
e
c
h
a
r
c
o
a
l
p
l
u
g
f
r
o
m
p
y
l
o
r
u
s
t
o
c
a
e
c
u
m
w
a
s
d
e
t
e
r
m
i
n
e
d
a
n
d
e
x
p
r
e
s
s
e
d
a
s
a
p
e
r
c
e
n
t
a
g
e
o
f
t
h
e
t
o
t
a
l
l
e
n
g
t
h
o
f
t
h
e
s
m
a
l
l
i
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(e.g.,E.coli(multi-drug-resistant(MDR)),S.aureus(MDR),
K. pneumoniae, B. cereus, V. cholera,a n dC. albicans)
using the agar well diﬀusion method with Ciproﬂoxacin
(50μg/mL) used as standard antibiotic. M. malabathricum,
in the volume of 50μL/well and in the concentration of
1.00mg/mL, was considered to possess moderate antimicro-
bial activity as indicated by its ability to produce zone of
inhibitionrangingbetween8to11mmagainstallpathogenic
microorganisms.Incomparison,Ciproﬂoxacinproducedthe
zone of inhibition ranging between 14 and 27mm. The
MIC value for the WMML, BMML and AcMML against
V. cholerae was 0.65, 0.80 and 0.80mg/mL while the MIC
value for the WMML and AcMML against S. aureus (MDR)
was 0.80 and 0.79, respectively. For E. coli (MDR), K. pneu-
m o n i a e ,C .a l b i c a n sand B. cereus, only the AcMML produced
MIC value, which was recorded at 0.62, 0.79, 0.80 and
0.80mg/mL,respectively.IntermoftheMBCvalue,thethree
extracts of M. malabathricum caused bactericidal activity
against V. cholera at the concentration of 0.90mg/mL while
the AcMML and BMML exerted bactericidal eﬀect against S.
aureus (MDR) at 1.00mg/mL. For E. coli (MDR), K. pneu-
moniae, C. albicans and B. cereus, the MBC value was
recorded only for the AcMML extract, which is at 0.70, 0.95,
0.90 and 0.90mg/mL, respectively. However, the MIC and
MBC value for Ciproﬂoxacin was not determined.
In an attempt to study the wound healing properties of
theleavesofwhiteM.malabathricumcollectedfromtheState
of Selangor, Malaysia, Sunilson et al. [66] also carried out
antibacterial study on the MMML against the four clinical
isolat es(A,B ,C,andD)ofS.aureusand3clinicalisolates(A,
B, and C) of P. aeruginosa obtained from sores of diﬀerent
patients using a modiﬁcation of the agar well diﬀusion
technique.Basedonthedataobtained,theextract,whichwas
tested in the concentrations of 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0,
and 16.0mg/mL, exhibited antibacterial activity at the MIC
value of 3.0mg/mL for A, B, and D and 7.0mg/mL for C
clinical strains of S. aureus, respectively. On the other hand,
the MIC value recorded for the three clinical isolates of P.
aeruginosa was 8.0mg/mL. However, no standard antibiotics
were used as references.
4.3. Antiviral Activity. Loh´ ezic-Le D´ ev´ ehat et al. [32]i n v e s -
tigated the antiviral activity of ten methanolic extracts
from eight Indonesian medicinal plants, which included M.
malabathricum,againstHSV-1andPoliovirus.Thevirustitre
was estimated from cytopathogenicity and expressed as 50%
tissue culture infectious doses per millilitre (TCID50/mL).
The antiviral activity was assayed using the cytopathic eﬀect
inhibition assay, which was expressed as EC50. The eﬀect of
extract on uninfected Vero cells was given by cytotoxic con-
centration 50% (CC50;μg/mL). The MMML together with
several species from the Indonesian Loranthaceae, which was
collected from Padang in the State of Andalas, Indonesia,
was reported to exert moderate anti-HSV-1 activity with
signiﬁcant activity against Poliovirus. The MMML exhibited
CC50 against HSV-1 and Poliovirus with value greater than
1000μg/mL (>1000μg/mL) or equal to 1000μg/mL, respec-
tively. In terms of EC50, the value recorded for treatment of
e x t r a c ta g a i n s tH S V - 1v i r u sa t2 0T C I D 50 and 200 TCID50
was 192 and 706μg/mL, while, for treatment against Polio-
virus, the EC50 value obtained at 20 TCID50 and 200 TCID50
was 111 and 225μg/mL, respectively.
Nazlina et al. [55] have studied the antiviral activity of
MMML. The extract earlier subjected to the TLC assays
resulted in the isolation and identiﬁcation of rutin, quer-
citrin, and quercetin. The antiviral activity was screened
against HSV-1 and vaccine strain of measles (Schwarz)
wherein three methods of treatment to detect antiviral
activity in each of the fraction were used (see Table 4). For
the antiviral tests, the extract was diluted at 1.0 LC50,0 . 1
LC50, and 0.01 LC50. The MMML exerted antiviral activity
with diﬀerent modes of action against HSV-1 or measles
viruses. The extract was eﬀective in inhibiting cell death by
0.01 LC50 in HSV-1-inoculated cells using treatment mode
((C+V)+E)suggestingthatvirus-inoculatedcellswereable
to overcome viral infection when treated with the extract.
Cellstreatedwithsimultaneousadditionofmeaslesvirusand
the extract at 0.1 and 1.0 LC50 were found to survive from
viral infection. The eﬀect of MMML is probably due to the
quercetincontentthatcaninhibitreversetranscriptasewhich
is the early part of the measles’ replication process. Another
possibility is that the MMML is capable of acting directly
o nv i r a lp a r t i c l es u c ha sm o d i ﬁ c a t i o no ff r e ev i r u s e ss u r f a c e s
that inhibits viral attachment to host cells. This belief was
supported by the fact that MMML was not capable of inhi-
biting virus-inoculated cells in treatment mode I. However,
the most probable mode of infection can only be further
conﬁrmed by transcriptomic or proteomic studies. The
extract was found not to have prophylactic eﬀect on both test
viruses as demonstrated in treatment mode ((C + E) + V).
As for control, guanidine hydrochloride is seen in this study
to inhibit viral capability of infecting host cells when added
simultaneously, which is believed to happen via blocking of
the initiation step of viral RNA synthesis.
4.4. Antiparasitic Activity. Alen et al. [67]h a v es c r e e n e d6 5
methanolic extracts of Sumatranrain forest plants, including
M. malabathricum, for their nematocidal activity against
Bursaphelenchus xylophilus using the in vivo cotton ball- (bl-
) fungal mat assay. The authors reported that the MMML,
togetherwiththatofAllamandacathartica,Ervatamiacorym-
bosa, Hoya diversifolia, Bischoﬁa javanica, Derris malaccensis,
Ophiorrhiza konsteleary,a n dBrucea sumatrana, exhibited
strong nematocidal activity with the recorded minimum
eﬀectivedose(MED)ofapproximately5mg/bl.However,the
extracts of Bischoﬁa javanica, Knema hookeriana and Areca
catechu were considered to be the most eﬀective nematocidal
agents with the recorded MED of approximately 0.7mg/bl.
4.5. Antioxidant Activity. Susanti et al. [22] have also studied
the antioxidant activity of the ethanolic solution of the crude
EAMMFw and MMMFw, as well as naringenin, kaemp-
ferol and kaempferol-3-O-D-glucoside isolated from the
EAMMFw and kaempferol-3-O-(2  ,6  -di-O-p-trans-cou-
maroyl)-β-glucopyranoside and kaempferol-3-O-D-gluco-
side isolated from the MMMFw. The antioxidant assay was
carried out by the DPPH radical scavenging electron spin
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vitamin C used as standard positive control. The ethanolic
solution of the test sample 100μl( 1 m g / m L )w a sa d d e d
to 100μl of DPPH (39.43M) in ethanol solution and sub-
jected to the assay. At the concentration of 7.8μg/mL, the
MMMFw exerted a stronger free radical scavenger activity
than the EAMMFw with the percentage of inhibition re-
corded at 59.3 ± 1.4% and 53.2 ± 1.3%. Naringenin, kaem-
pferol, kaempferol-3-O-D-glucoside, and kaempferol-3-O-
(2  ,6:-di-O-p-trans-coumaroyl)-β-glucopyranoside, at the
concentration of 7.8μg/mL, were found to produce 42.5 ±
0.7%, 38.6±0.09%, 24.6±0.3%, and 31.2±4.5% inhibition
in comparison to vitamin E and vitamin C, which produced
50.9 ± 0.07% and 82.2 ± 0.3% inhibition, respectively. The
IC50 recorded for MMMFw, EAMMFw, naringenin, kaem-
pferol, kaempferol-3-O-D-glucoside, kaempferol-3-O-(2  ,
6  -di-O-p-trans-coumaroyl)-β-glucopyranoside were 6.59±
0.8μg/mL, 7.21 ± 0.5μg/mL, 0.52 ± 0.5mM,81.5 ± 0.7μM,
1.07 ± 0.4mM, 35.8 ± 0.5μM, respectively. According
to Susanti et al. [22] kaempferol-3-O-(2  ,6:-di-O-p-trans-
coumaroyl)-β-glucopyranoside was a more active antioxi-
dant than the other compounds and this pronounced rad-
ical-scavenging activity is due to the presence of two p-cou-
maroyl acid groups which are located at the 200 and 600
positions in the glucose ring. Thus, it is proposed that the
presence of compound 4 contributed to the higher antiox-
idant activity of the MMMFw. Meanwhile the authors also
suggested that naringenin exhibited a less active antioxidant
activity when compared to kaempferol or kaempferol-3-O-
D-glucoside due to the lack of an unsaturated heterocyclic
ring(C-ring),whichallowselectrondelocalization acrossthe
molecule for stabilization of the aryloxyl radical, as well as
the lack of a 3-OH group.
The antioxidant potential of HMML, EAMML, and
MMML of white petals M. malabathricum,c o l l e c t e df r o m
Johor, Malaysia, together with the isolated compounds (e.g.,
α-amyrin, patriscabatrine and auranamide, quercetin, quer-
citrin, and kaempferol-3-O-(2  ,6  -di-O-p-trans-couma-
royl)glucoside), was determined using the ferric thiocyanate
(FTC) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) (UV and
ESR spectroscopic) methods [56]. In the former assay, the
ﬁnal concentration of test solution was 0.02% w/v, while,
in the latter assay, the concentration of test solutions used
were 500, 250, 125, 62.5, 31.3 and 7.8μg/mL. From the data
obtained, kaempferol-3-O-(2  ,6  -di-O-p-trans-coumaroyl)
glucoside, kaempferol-3-O-β-D-glucose, kaempferol, hype-
rin, quercetin, and quercitrin showed strong antioxidative
activitiesthanvitaminEwithinhibitionofmorethan90%in
the FTC method. Quercetin, quercitrin, and kaempferol-3-
O-(2  ,6  -di-O-p-trans-coumaroyl)glucoside) produced the
respectivepercentageoflinolenicacidperoxidationof96.1%,
94.1%, and 92.2%, which is greater than vitamin E (78.3%).
In the DPPH assay, quercetin was found to be the most
active free radical scavenger in DPPH-UV and ESR method
withIC50 of 0.69 and 0.65μM, respectively. The IC50 value of
quercetin in the DPPH-UV method was greater than that of
the positive control, vitamin E (17.1 ± 2.5mM) and vitamin
C( 8 .3±1.2μM) and the other ﬂavonoids, namely, quercitrin
(74.1 ± 0.4μM) and kaempferol-3-O-(2  ,6  -di-O-p-trans-
coumaroyl)glucoside) (308.1 ± 1.7μM). The percent inhi-
bition of quercetin, quercitrin, kaempferol-3-O-(2  ,6  -di-
O-p-trans-coumaroyl)glucoside), vitamin E, and vitamin C
at concentration 7.8μg/mL was 57.60%, 15.4%, 7.5%, 7.4%,
and 30.8%, respectively.
In addition, Faravani [58] also reported the antioxidant
activity of crude MMMR and methanol extracts of M. mala-
bathricum shoots (MMMSt) investigated using the DPPH
assay.TheMMMStexhibitedtheirradicalscavengingactivity
as indicated by their ability to reduce the stable free-rad-
ical DPPH to the yellow-colored diphenylpicrylhydrazine
with an IC50 recorded at approximately 141.9μg/mL and
154.5μg/mL, respectively. However, the extracts antioxidant
activitywasconsideredtobeloweredthanthatofthepositive
control, ascorbic acid, which produced an IC50 of approxi-
mately 28.6μg/mL.
4.6.CytotoxicActivity. Anattempttodeterminethecytotoxic
activity of MMML together with nine methanolic extracts
from seven Indonesian medicinal plants was also made by
Loh´ ezic-Le D´ ev´ ehat et al. [32]. All plants were collected from
Padang in the State of Andalas, Indonesia, and subjected to
the cytotoxic study on two murine cancer cell lines (e.g.,
3LL (Lewis lung carcinoma cells) and L1210 (leukaemic
cells)) and four human cancer lines (e.g., K562 (chronic
myeloid leukaemia), U251 (glioblastoma), DU145 (prostatic
adenocarcinoma), and MCF-7 (mammary carcinoma)). The
MMML exhibited cytotoxic activity against 3LL, L1210,
K562, DU145, MCF-7, and U251 at the IC50 values of 19, 21,
67,113,>400,and30μg/mL.Interestingly,MMMLexhibited
cytotoxic activity with IC50 value of <25μg/mL against both
murine cell lines while the cytotoxicity activity against all
human cancer cell lines was observed at an IC50 value that
was >25μg/mL.
Susanti et al. [22] have investigated cytotoxic activity of
the crude EAMMFw and MMMFw and several compounds
isolated from the respective crude extract (e.g., naringenin,
kaempferol and kaempferol-3-O-D-glucoside, kaempferol-
3-O-(2  ,6  -di-O-p-trans-coumaroyl)-β-glucopyranoside,
and kaempferol-3-O-D-glucoside) against a MCF-7 cell line
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay. DMSO (0.1%) and tamoxifen
were used as negative and positive controls, respectively. The
500μg/mL EAMMFw caused a change in the cell morpho-
logy of MCF-7 cells line, while MMMFw, at the same con-
centration, did not display any activity. Naringenin and
kaempferol-3-O-(2  ,6  -di-O-p-trans-coumaroyl)-β-gluco-
pyranoside demonstrated a signiﬁcant anticancer eﬀect
against MCF-7 in a dose-dependent manner with IC50 values
of 1.30 ± 0.002μMa n d0 .28 ± 0.004μM, respectively. The
anticancer activity of those compounds was demonstrated to
involve cell proliferation and changes in the cell morphology.
Thus, naringenin was suggested to contribute to the anti-
cancer activity of the EAMMFw. The failure of MMMFw to
exhibit its cytotoxicity eﬀect suggested that the antagonist
eﬀects of the compounds present in the extract play an
important role in not aﬀecting the cell proliferation.
Interestingly, the IC50 value of kaempferol-3-O-(2  ,6  -di-
O-p-trans-coumaroyl)-β-glucopyranoside was lower than
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was 0.76 ± 0.005μM). Based on the cell morphology, it
was proposed that kaempferol-3-O-(2  ,6  -di-O-p-trans-
coumaroyl)-β-glucopyranoside was active against human
breast cell cancer by inhibiting cell proliferation. Meanwhile,
naringenin inhibited cell proliferation, followed by cell lyses.
Kaempferol-3-O-(2  ,6  -di-O-p-trans-coumaroyl)-β-gluco-
pyranoside has a free hydroxyl group at position 3 and a
parahydroxyl group in ring B, which probably increase the
activity of this compound.
Nazlina et al. [55] have also studied the cytotoxic activity
of MMML against Vero cell line (African green monkey, Cer-
copitheus aethiops kidney cells) and L929 cells (mouse ﬁbro-
blast) whereby the cytotoxicity test was carried out according
to the microculture method in, at least, two independent
experiments in triplicates at diﬀerent concentrations of
MMML using doubling dilutions from initial stock concen-
tration of 1000μg/mL. Cytotoxicity screening towards Vero
and L929 cells showed that MMML was not cytotoxic to
both cells with LC50 values of 750μg/mL and >1000μg/mL,
respectively. As for gunaindine hydrochloride that was used
as positive control, it was found not cytotoxic in Vero cells
with the LC50 value of 100μg/mL while the LC50 value for
L929 cells was not determined.
4.7. Anticoagulant Activity. Manicam et al. [68]h a v er e p o r -
ted on the anticoagulant property of the leaves of M. mala-
bathricum collected from the area of Serdang in the state of
Selangor, Malaysia. The hot- and cold-WMML and MMML
wereassayedfortheiranticoagulantpropertyusingtheblood
samples drawn from healthy volunteer donors (n = 36)
of both genders (18–50 years old) after screening via ques-
tionnaire for familial history of cardiovascular diseases and
other major coagulopathies. The coagulation parameters
usedtodeterminetheextractsanticoagulantactivitywerethe
activated partial thromboplastin time (aPTT), prothrombin
time (PT), and thrombin time (TT). These parameters were
carried out in a STA Compact coagulation analyzer with the
maximum cut-oﬀ time recorded by the coagulation analyzer
set at 180s. Plasma samples were spiked with diﬀerent con-
centrations of M. malabathricum extracts (ranging between
100 and 1000μg/mL), heparin (used as positive control),
or deionized water (used as vehicle control). Based on the
preliminary study, the hot-WMML, in the concentration of
1000μg/mL, signiﬁcantly prolonged (P<0.05) the three
parameters, namely, aPTT, PT, and TT, in plasma when
compared to the normal control plasma. The PT and TT
measurements were 20.0 ± 1.3sand43.2 ± 0.1swhencom-
paredtocontrolgroup(13.3±0.5or20.1±0.2s),respectively.
Interestingly, the hot-WMML did not clot the plasma
sampleswhentestedforaPTT,asevidencedbythemaximum
cut-oﬀtimerecordedat180s.Thecold-WMMLandMMML
also prolonged aPTT in a signiﬁcant fashion (P<0.05) with
120.0 ± 0.9s and 108.0 ± 0.7s, respectively, in comparison
to the 38.9 ± 0.5s of control plasma. Similar to the hot-
WMML,thePTofcold-WMMLwasprolongingsigniﬁcantly
(P<0.05) in comparison to the control. On the other hand,
these extracts did not aﬀect the TT signiﬁcantly. Based on
the anticoagulant activity demonstrated above, at the con-
centration of 1000μg/mL, Manicam et al. [68] selected the
hot-WMML for further study on its eﬀect on clot-based
assays. At the concentration ranging between 100 to
1000μg/mL, the hot-WMML caused prolongation of aPTT
in a concentration-dependent manner with signiﬁcant anti-
coagulant activity recorded at the concentration beyond
400μg/mL in comparison with vehicle control. Interestingly,
hot-WMML prolonged aPTT beyond 300s at 900 and
1000μg/mL, which was comparable to that of 5–1000μg/mL
heparin. The cut-oﬀ time to measure clotting times was
300s; beyond which the plasma samples were rendered non-
coagulable. The control plasma was found to record an aPTT
of 64.3 and 60.7s for females and males, respectively. On the
other hand, the aPTT of normal pooled plasma (NPP) was
41.0 and 40.5s for females and males, respectively, and was
signiﬁcantly diﬀerent (P<0.05) from that of the control
plasma. In contrast to aPTT, hot-WMML caused no signif-
icant changes for PT and TT at the tested concentration
range. However, PT was signiﬁcantly (P<0.001) prolonged
at the highest contration of heparin (1000μg/mL) while TT
was signiﬁcantly (P<0.001) prolonged at the highest con-
centration of hot-WMML (1000μg/mL) or at the range of
5–1000μg/mL. Overall, the PT assay recorded the lowest
coagulation inhibitory activity for hot-WMML.
4.8. Platelet-ActivatingFactor Inhibitory Activity. Jantan et al.
[69]investigatedtheanti-platelet-activatingfactorinhibitory
property of 49 methanol extracts of 37 species of Malaysian
medicinal plants, including M. malabathricum collected
from Kepong, Shah Alam, Selangor, Malaysia. However, the
MMML, at the concentrations of 200, 100, 50, 20 and
10μg/mL, produced <10% inhibitory eﬀect against platelet
activating factor (PAF). Cedrol, a known PAF receptor anta-
gonist and at the concentration of 18.2μg/mL, was used as a
standard in the bioassay.
Mazura et al. [70], in their quest for natural anti-inﬂam-
matory agents, assessed the potential of α-amyrin, betulinic
acid, quercetin and quercitrin isolated from M. malabath-
ricumtoinhibitPAFbindingtorabbitplateletsusing 3H-PAF
as a ligand. At 18.2μg/mL, all compounds exerted 67.3, 64.3,
57.4, and 45.4%, while cedrol, as positive control, caused
79.6%, respectively. The tested compounds, at the serial con-
centration dilution range of 18.2–1.8μg/mL, produced the
percentage of inhibition (%) of 17.9–70.4%, 11.8–65.1%,
4.3–58.9%, and 2.5–44.8%, respectively. The results also in-
dicated that quercetin, quercitrin, α-amyrin, and betulinic
acid showed inhibition of PAF receptor binding to rabbit
platelets with IC50 values of 33.0, 45.4, 20.0, and 22.2μM,
respectively. The IC50 values of these compounds were com-
parable to that of cedrol (13.1μM), which is a known PAF
receptor antagonist.
4.9.WoundHealingActivity. Sunilsonetal.[66]reportedthe
wound healing potential of MMML, collected from the State
of Selangor, Malaysia, in the form of ointment when exa-
mined in two types of wound model in rats: (i) the excision
wound model and (ii) the incision wound model. The ext-
ract, prepared as 5% ointment, exhibited a wound healing
activity that was comparable with the standard drug, nitro-
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of wound contracting ability, wound closure time, tensile
strength, and regeneration of tissues at the wound site. The
time to wound closure of the nitrofurazone- and the extract-
treated groups was the same (18.0±2.0 days). In the incision
wound studies, the extract ointment and nitrofurazone
caused a signiﬁcant increase in tensile strength of the 10-
day-old wound when compared with the control (418.0 ±
13.8g). The tensile strength of the extract ointment- and
the nitrofurazone-ointment-treated groups was almost the
same (551.0 ± 16.9g versus 576.0 ± 12.5g). Interestingly,
the extract ointment enhanced original tissue regeneration
of the skin wounds much greater than nitrofurazone with
the standard drug exerting more relative ﬁbrosis of skin
wounds when compared to the extract ointment. Although
ﬁbrosis was relatively less in the extract ointment-treated
rats, the original tissue was regenerated much more in the
animal wounds. The skin adrenal structures such as the
Pilosebaceous glands and sweat glands were better presented
in wounds treated with extract ointment compared to nitro-
furazone-treated animal wounds.
4.10.AntiulcerActivity. Hussainetal.[71]studiedtheantiul-
cer activity of the AMML, collected around the University of
Malaya campus in Petaling Jaya, Selangor, Malaysia, against
ethanol-induced gastric mucosal injuries in rats. The extract,
in the dose of 250 and 500mg/kg, and 20mg/kg omeprazole,
used as positive control, were administered orally followed 1
hour later by the oral administration of the ethanol. Macro-
scopically, the oral administration of the test solutions was
found to signiﬁcantly (P<0.05) reduce the formation of
gastric mucosal injuries in a dose-dependent manner when
comparedtothegroupthatwaspretreatedwithonlydistilled
water. The ulcer area recorded for groups pretreated with
distilled water, 250 and 500mg/kg extract, and 20mg/kg
omeprazole was 845.00 ± 52.17mm2, 210.00 ± 8.17mm2,
70.00±8.27mm2 and30.00±5.32mm2,respectively .Interms
of percentage of protection, the respective test solution was
found to give approximately 75.15%, 91.72%, and 96.45%
protection. Microscopically, distilled-water-pretreated rats
exhibited severe damage of the gastric mucosa, and induced
submucosal edema and leucocytes inﬁltration while extract-
or omeprazole-received rats exerted marked reduction of
gastric mucosal damage, reduction of oedema, and less leu-
cocyte inﬁltration of submucosal layer. There were no sig-
niﬁcantdiﬀerencesbetweenthecytoprotectiveabilitiesofthe
animals treated with 20mg/kg omeprazole compared to
the animals treated with 500mg/kg AMML. Overall, the
500mg/kg AMML was found to provide the best protection
to the gastric mucosa in rats against ethanol-induced gastric
ulcers.
4.11. Antidiarrheal Activity. The antidiarrheal activity of
WMML, collected from the State of Selangor, Malaysia, was
investigated using four experimental models of diarrhea in
mice [61]. In model 1, mice were given test solutions (e.g.,
100, 200, and 500mg/kg of extract or 5mg/kg loperamide)
and fecal materials were collected for 12h after treatment,
dried in an incubator, and weighed. The percentage reduc-
tion in the fecal output was determined. In model 2, an
overnight fasted male mouse was induced with diarrhea by
oral administration of castor oil (0.5mL/mouse, p.o.) 1 hour
after the test solutions administration. The percentage pro-
tection from diarrhoeal droppings was calculated. In model
3, overnight fasted mice were subjected to the enteropooling
assay method wherein the animals received the test solutions
and, 1 hour later, administered orally with a diarrheal agent,
10% aq MgSO4 (0.5mL/mouse). Thirty min later, the ani-
mals were killed and the small intestines were collected and
weighed to ﬁnd out the accumulation of intestinal ﬂuid
secretion evoked by MgSO4. In model 4, the overnight fasted
animals were subjected to the gastrointestinal transit test.
The animals received test solutions, and, 5min later, 0.5mL
of 3% charcoal suspended with tragacanth powder was
administered orally to each mouse. Thirty min later, all the
mice were killed by cervical dislocation and the distance
travelled by the charcoal plug from pylorus to caecum was
determined and expressed as a percentage of the total length
of the small intestine. From the data obtained in model 1,
100, 200, and 500mg/kg WMML signiﬁcantly (P<0.05)
reducedthedriedfecaloutputofthemice(driedfecaloutput
per 100g of mice) by 0.364 ± 0.012 (30.13% reduction),
0.314±0.046(39.73%reduction),and0.296±0.023(43.19%
reduction), respectively, while the reduction in the fecal
output by loperamide (5mg/kg) was noted to be 0.222 ±
0.015 (57.39% reduction) when compared to the control
group (0.521±0.083). In model 2, the WMML, at its respec-
tive dose, signiﬁcantly (P<0.05) protected the mice against
castor-oil-induced diarrheal droppings by 60, 80 and 80%,
whileloperamideproducedthe100%protection.Inmodel3,
the 100, 200, and 500mg/kg WMML signiﬁcantly (P<0.05)
and dose-dependently reduced the intestinal ﬂuid secretion
induced by MgSO4, with the weight of the small intestine per
100g of mice recorded at 8.413 ± 0.431, 7.620 ± 0.469, and
7.314 ± 0.261 when compared to the control group (9.362 ±
0.518). Interestingly, 500mg/kg WMML caused reduction in
theintestinalﬂuidsecretionthatwasalmostcomparablewith
that of 5mg/kg loperamide (6.416 ± 0.514). In model 4, the
100, 200 and 500mg/kg WMML signiﬁcantly (P<0.05)
inhibited the small intestinal motility of the charcoal marker
in mice in a dose-dependent manner by 8.10%, 25.15%,
and 32.97% inhibition in comparison to 5mg/kg loperamide
(57.42% inhibition). The respective distance travelled by
charcoal marker for each dose of extract presented as per-
centage of total length of small intestine was recorded at
63.63 ± 3.71, 51.82 ± 4.11 and 46.41 ± 3.25 when compared
to the control group (69.24 ± 5.03) or 5mg/kg loperamide
(29.48 ±2.69).
4.12. Antivenom Activity. Uawonggul et al. [72] reported the
antivenom proﬁle of the aqueous extracts of 64 plant species,
including M. malabathricum, collected from northern and
northeastern parts of Thailand and have been listed as ani-
mal- or insect-bite antidotes in old Thai drug recipes. The
extracts, at the concentration of 0.406 and 0.706mg/mL,
were screened for their activity against ﬁbroblast cell lysis
after Heterometrus laoticus scorpion venom treatment. H.
laoticus scorpions were captured from suburban areas of
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plants, at the concetration of 0.706mg/mL, were found to
give more than 40% eﬃciency following cell treatment with
venom preincubated with the respective extract with Andro-
graphis paniculata Nees (Acanthaceae) and Barringtonia acu-
tangula (L.) Gaertn. (Lecythidaceae) given more than 50%
eﬃciency, indicating that they had a tendency to be scor-
pion venom antidotes. However, AMML only caused
39.86% eﬃciency at 0.706mg/mL and 34.41% eﬃciency at
0.406mg/mL. The percentage of viable cells after 30min
treatmentwith0.706and0.406mg/mLAMMLpreincubated
with 0.2μg/mL H. laoticus venom were 14.84 ± 1.03 and
14.11 ±1.03 in comparison to their respective mock control,
which is 37.23 ±0.34 and 41.00 ± 0.52, respectively.
4.13. Anti-Inﬂammatory Activity. Zakaria et al. [30]r e po rt ed
on the anti-inﬂammatory activity of AMML, collected from
ShahAlam,Selangor,Malaysia.Theanti-inﬂammatoryactiv-
ity was determined using only the carrageenan-induced paw
edema wherein the extract, at the concentration of 10%,
50%, and 100%, was administered via subcutaneous route
and measurement of paw thickness was carried out for
8 hours following the extract administration with 1-hour
interval. The concentration of AMML used was equivalent
to the doses of 4.87, 24.35, and 48.7mg/kg, respectively. The
AMML was found to show signiﬁcant (P<0.05) anti-in-
ﬂammatory activity in a concentration-independent manner
wherein the activity was seen only at the 50% and 100%
concentrations. In terms of the onset of action, the AMML
exhibited the anti-inﬂammatory activity 1 hour after its
subcutaneous administration and this activity was seen until
the end of experiments. Interestingly, 100mg/kg acetylsal-
icylic acid (ASA), used as positive control, exerted similar
strength of anti-inﬂammatory when compared to the extract
as indicated by the statistically insigniﬁcant data at the res-
pective time interval.
Susanti et al. [56] investigated the anti-inﬂammatory ac-
tivity of pure compounds obtained from HMML, EAMML
and MMML using the 12-O-tetradecanoylphorbol-13-ace-
tate- (TPA-) induced mouse ear oedema assay. The pure
compound (20μL) was applied topically to the inner surface
of the right ear of the mice with the left ear receiving
only vehicle acting as negative control group. The pure com-
pounds (0.5mg/ear) and the standard drug indomethacin
(0.5mg/ear) were applied topically, simultaneous with TPA.
From the results obtained, 0.5mg/mL kaempferol-3-O-
(2  ,6  -di-O-p-trans-coumaroyl) glucoside and α-amyrin
demonstrated the strongest activities in the anti-inﬂamma-
tory assay with the IC50 of approximately 0.11 ± 0.4a n d
0.34±1.1mM/ear,respectivelyascomparedtothe0.5mg/mL
indomethacin (2.10±0.5mM/ear). However, no data on the
anti-inﬂammatory eﬀe c to ft h o s ec r u d ee x t r a c t sw e r eg i v e n
for comparison with their pure compounds.
4.14. Antinociceptive Activity. The ethanolic extract of M.
malabathricum stem barks and leaves (EMMSBL), collec-
ted from Serdang, Selangor, Malaysia, was earlier studied
its antinociceptive activity using the acetic-acid-induced
abdominal constriction and hot plate test in mice [73]. The
extract,administeredintraperitoneallyinthedosesof30,100
and 300mg/kg, was found to exert potential (P<0.05) anti-
nociceptive activity in a dose-dependent manner in the
former test with the percentage of nocicptive inhibition
recorded at 23.0%, 50.0%, and 84.4%, respectively. The
ED50 recorded was approximately 100mg/kg when given
intraperitoneally. ASA, at 100mg/kg dose, produced 79.0%
nocicptive inhibition. In the latter test, the extract signiﬁ-
cantly (P<0.05) increased the response latency period to
thermal stimuli in mice also in a dose-dependent manner.
The antinociceptive activity of EMMSBL reached its peak
approximately 60min after the extract administration. Mor-
phine, at 5mg/kg dose, signiﬁcantly (P<0.05) prolonged
the response latency period with maximum eﬀect obtained
approximately 1h after treatment. In an attempt to deter-
mine the role of opioid receptors in mediating the EMMSBL
antinociceptive activity, 5mg/kg naloxone, a nonselective
opioid antagonist given via intraperitoneal route 15min
before the extract, was found to inhibit the antinociceptive
activity of the extract in both tests.
Zakaria et al. [30] reported on the antinociceptive acti-
vity of the AMML, collected from Shah Alam, Selangor,
Malaysia. The antinociceptive activity of subcutaneously ad-
ministered extract, at the concentration of 10%, 50%, and
100% (which is equal to the dose of 4.87, 24.35, and
48.7mg/kg, resp.), was determined using the acetic acid-in-
duced abdominal constriction, hot plate and formalin test.
The AMML was found to show signiﬁcant (P<0.05) anti-
nociceptive activity in all the three tests. In the acetic-acid-
induced abdominal constriction test, all concentrations of
AMML caused signiﬁcant (P<0.05) reduction in the
number of abdominal constriction which occur in a con-
centration-independent manner. The 10%, 50%, and 100%
AMML exerted similar strength in antinociceptive activity
when compared together or against 100mg/kg ASA. In the
hot plate test, all concentrations of AMML also exhibited
a signiﬁcant (P<0.05) antinociceptive activity in a con-
centration-independent manner with only the 50% and
100% concentrations of AMML exerting an antinociceptive
activity that lasted until the end of the experiment. In this
test, 5mg/kg morphine was used as a positive control and
was more eﬀective in increasing the latency to feel thermal-
induced pain when compared to the extract. In the formalin
test, the AMML at all concentrations used exerted antinoci-
ceptive activity in both the early and late phases of the test.
The concentration-dependent activity was observed only in
the late phase of the test.
4.15. Antipyretic Activity. Zakaria et al. [30] also reported
on the antipyretic activity of AMML, collected from Shah
Alam, Selangor, Malaysia. The antipyretic activity of subcu-
taneouslyadministeredAMML,attheconcentrationof10%,
50% and 100%, was determined using the Brewer’s Yeast-
(BY-) induced pyrexia test. The ability of M. malabathricum
extract to reduce temperature of pyrexia induced rats was
determinedfor8hourswith1-hourinterval.TheAMMLwas
found to show signiﬁcant (P<0.05) antipyretic activity at
all concentrations tested for the ﬁrst 6 hours after BY admin-
istration. A rapid decrease in the antipyretic activity of the
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when compared with the other concentrations of AMML,
with completely diminished activity observed for the last
2h of the experiment. The 100mg/kg ASA demonstrated
antipyretic activity only for the ﬁrst 4 hours before the acti-
vity was gradually lost until the end of experiment.
5. Discussion and Conclusion
According to Mitchell and Ahmad [74], the wealth of a
country resides to a large extent in its plant inheritance,
regardless of whether the plants are endemic, naturalized, or
recentintroductions.Outofatotalofmorethan4000species
of Melastomataceae plants in the world, M. malabathricum
has been one of the 22 species found in the Southeast Asian
region alone [1] and one of the 12 species found in Malaysia.
Considered as native to tropical and temperate Asia and the
Paciﬁc Islands [4], this commonly found small shrub has
g a i n e dh e r b a ls t a t u si nt h eM a l a yf o l k l o r eb e l i e fa sw e l la s
the Indian, Chinese, and Indonesian folk medicines. Despite
claims that this plant was one of the important herbs within
the traditional Malay, Indian, and Chinese medicine, no
proper documentation could be found to support them. For
example, no documentation that provides proofs for the
claims of the importance of M. malabthricum in traditional
Chinese medicine could be found when the authors carried
out thorough search via university or public libraries, as
well as the internet. Various parts of this shrub have been
c l a i m e dt ob eu s e di nt h et r e a t m e n to fv a r i o u st y p e so fa i l -
ments and diseases (e.g., diarrhoea, dysentery, leucorrhoea,
hemorrhoids, cuts and wounds, infection during conﬁne-
ment, toothache, stomachache, ﬂatulence, sore legs, and
thrush) with most of them not yet proven via clinical studies
[23]. Despite the lack of clinical studies related to this plant,
several attempts have been made to elucidate the pharmaco-
logical properties of M. malabathricum using the standard
and scientiﬁc in vitro and in vivo techniques of biological
evaluations and to ﬁnally conﬁrm those folklore claims.
Present interests towards the medicinal beneﬁts of herbal
medicines have been increasing worldwide as can be seen
with increased laboratory investigation into the pharmaco-
logical properties of various medicinal plants. Scientists have
also been involved in the isolation, identiﬁcation, and deter-
mination of the bioactive ingredients with speciﬁc ability to
treat various diseases [75]. Various drugs have entered the
international market as a result of scientiﬁcally in-depth
and systematic exploration of ethnopharmacology and tra-
ditional medicine. Despite the increase in scientiﬁc study to-
wards medicinal plants all over the world, a smaller number
of phytochemical entities or drugs have entered the local
or international market due to their evidence-based ther-
apeutics [74]. Due to the latter market trend, eﬀorts are
needed to ascertain and conﬁrm evidence regarding safety
and practices of plant-based medicines. Furthermore, plant-
based medicines are erroneously considered safe because
they are regarded as naturally occurring and of plant origin.
According to Yob et al. [76], the lack of scientiﬁc and
clinical data has led to poor understanding of the eﬃcacy
and safety of the herbal drugs, which in turn contributes to
major impediment in the use of plant-based medicinal pre-
parations. The only attempt to establish acute toxicity proﬁle
of M. malabathricum was performed by Sunilson et al. [61].
The authors reported the nontoxic eﬀect of WMML up to
the dosage of 2000mg/kg when given to mice. This indicates
that the WMML is safe for consumption even at the highest
dosage (2000mg/kg) tested and justiﬁes the traditional uses
of M. malabathricum.
T h ed o s a g er a n g eu s e df o rin vivo study was very impor-
tantto corroboratewiththedosages usedin traditional med-
icine and the selection of dosage range should not exceed
the maximum tolerated dose (MTD) of 1000mg/kg/day sug-
gested for in vivo studies [77]. Based on MTD, the dosage
range used for in vivo antiulcer, antidiarrheal, antinocicep-
tive, anti-inﬂammatory, and antipyretic activities, which is
between 4 and 500mg/kg, was considered acceptable. In the
in vitro studies, the pharmacological activities shown have
to be interpreted cautiously depending on the EC50 or IC50
value obtained for the respective study [76]. According to
Meyer et al. [78] for any compounds/extracts to be consid-
eredactive,theyneedtoexhibittherespectiveactivityatEC50
or IC50 v a l u eo fl e s st h a no re q u a lt o3 0μg/mL (≤30μg/mL).
Based on this suggestion, the antibacterial, antiviral, antipar-
asitic,andantivenomactivitieswereobservedatEC50 orIC50
values that are unrealistic and greater than 30μg/mL, and,
thus, should be ignored. Some of the potential activities of
M. malabathricum, as indicated by EC50 or IC50 value of
≤30μg/mL, include antifungal, antioxidant, and cytotoxic
activities. The MMML, CMML, and AcMML exhibited anti-
fungal activity against C. gloeosporioides with MIC of
20μg/mL [64]. The MMMFw and EAMMFw exerted antiox-
idant activity in the DPPH assay at the IC50 of 6.59 ±
0.8μg/mL and 7.21 ± 0.5μg/mL, respectively [22]. The
MMMFw was also reported to show cytotoxic eﬀect against
3LL, L1210, and U251 cell lines at the IC50 values of 19,
21, and 30mg/mL, respectively [32]. Another major ﬂaw in
some of the reports cited above was failure of the authors
to provide proper comparison with reference drug [76]. The
importanceandreasonforchoosingcertainroutesofadmin-
istration and in vitro rather than in vivo assays in some of the
studies have been discussed by Yob et al. [76].
In this paper, we intended to brieﬂy summarize the in
vitro and in vivo assays applied in the discovery of possibly
new pharmacological agents from M. malabathricum.I na d -
dition, various literatures pertinent to the pharmacological
investigation of M. malabathricum were reviewed to gather
all information related to the ethnobotanical, phytochemi-
cal, and pharmacological properties of M. malabathricum.
Although various scientiﬁc papers were published on phar-
macological properties of M. malabathricum,d e t a i l e da n d
careful analysis revealed that M. malabathricum only exhib-
ited promising antiulcer, antidiarrheal, antinociceptive, anti-
inﬂammatory, and antipyretic activities as measured via the
various in vivo assays and antifungal, antioxidant, and cyto-
toxic activities as measured by the in vitro assays.
Despite the various medicinal uses of M. malabathricum
as described in the ethnobotanical section, the therapeutics
eﬃcacy of this plant has not been fully studied indepth.
Even though there are various types of bioactive com-
pounds isolated and identiﬁed from M. malabathricum as46 Evidence-Based Complementary and Alternative Medicine
highlighted in the phytochemical section, their contribution
towards the plant claimed medicinal uses or demonstrated
pharmacological activities were also not fully studied. Thus,
the quest for new compounds from M. malabathricum with
speciﬁc pharmacological activity remains unsolved. It is sug-
gested that researches should be increased to isolate, identify,
and collect most of the reported new compounds from M.
malabathricum so that their pharmacological potential could
be investigated thoroughly if they were to be developed as
candidates for new drug development in the future. In con-
clusion, it is hoped that this paper will serve as an encour-
agement for others to further explore the pharmacological
potentials of M. malabathricum with hope of developing it
as a new therapeutic agents as it is considered as one of the
importantherbs,particularlyintheMalayfolkloremedicine.
Acknowledgments
The authors thank the Faculty of Medicine and Health Sci-
ences, Universiti Putra Malaysia for providing the necessary
support for this study. This research was supported by a
Research University Grant Scheme 2010 (04/02/10/0925RU)
from the Universiti Putra Malaysia.
References
[1] M. T. Rajenderan, “Ethno medicinal uses and antimicrobial
properties of Melastoma malabathricum,” SEGi Review, vol. 3,
pp. 34–44, 2010.
[2] K. Meyer, “Revision of the Southeast Asian genus Melastoma
(Melastomataceae),” Blumea: Journal of Plant Taxonomy and
Plant Geography, vol. 46, no. 2, pp. 351–398, 2001.
[ 3 ]J .L .C .H .v a nV a l k e n b e r ga n dN .B u n y a p r a p h a t s a r a ,“ Melas-
toma malabathricum L.,” in Plant Resources of South-East Asia
No. 12(2): Medicinal and Poisonous Plants 2,J .L .C .H .v a n
Valkenburg and N. Bunyapraphatsara, Eds., pp. 365–366,
Backhuys, Leiden, The Netherlands, 2001.
[4] K. H. Ling, C. T. Kian, and T. C. Hoon, A Guide to Medicinal
Plants.AnIllustrated,ScientiﬁcandMedicinalApproach,W orld
Scientiﬁc, Singapore, 2009.
[5] W. Wong, Melastoma malabathricum: Too Beautiful to Be Cal-
led a Weed, Green Culture, Singapore, 2008.
[6] F. A. Abdul Majid and L. Y. Ting, “Basic in vitro studies
of human skin culture: Melastoma malabathricum extract
on ﬁbroblasts growth,” February 2011, http://eprints.utm.my/
2850/1/75127.pdf.
[7] A. S. M. Fazlin, Z. Ahmad, and H. H. Lim, Compendium of
Medicinal Plants Used in Malaysia, vol. 2, Herbal Medicine
Research Centre, Institute for Medical Research, Kuala Lum-
pur, Malaysia, 2002.
[8] P .W .Grosv enor ,P .K.Gothard,N.C.M cW illiam,A.Supriono ,
and D. O. Gray, “Medicinal plants from Riau Province, Suma-
tra,Indonesia.Part1:uses,”JournalofEthnopharmacology,vol.
45, no. 2, pp. 75–95, 1995.
[9] G. Umali-Stuart and A. Stiuart-Santiago, “Phillippine Medic-
inal Plants: Family Melastomaceae,” February 2010, http://
www.stuartxchange.org/Malatungaw.html.
[10] W. Zhengyi, P. H. Raven, and D. Y. Hong, Flora of China
(Vol. 13) (Clusiaceae through Araliaceae), Missouri Botanical
Garden Press, St. Louis, Mo, USA, 2007.
[11] H. K. Sharma, L. Chhangte, and A. K. Dolui, “Traditional
medicinal plants in Mizoram, India,” Fitoterapia, vol. 72, no.
2, pp. 146–161, 2001.
[12] A.D.Khumbongmayum,M.L.Khan,andR.S.Tripathi,“Eth-
nomedicinal plants in the sacred groves of Manipur,” Indian
Journal of Traditional Knowledge, vol. 4, pp. 21–32, 2005.
[13] C. Pattanaik, C. Sudhakar Reddy, and M. S. R. Murthy, “An
ethnobotanical survey of medicinal plants used by the Didayi
tribe of Malkangiri district of Orissa, India,” Fitoterapia, vol.
79, no. 1, pp. 67–71, 2008.
[14] H.N.Thatoi,S.K.P anda,S.K.Rath,andS.K.Dutta,“ Antimi-
crobial activity and ethnomedicinal uses of some medicinal
plantsfromSimilipalBiosphereReserve,Orissa,”AsianJournal
of Plant Sciences, vol. 7, no. 3, pp. 260–267, 2008.
[15] C. L. Ringmichon, S. N. Shimpi, and B. Gopalkrishnan, “Eth-
nomedicinalinvestigationsofMelastomamalabathricumLinn.
fromManipur,”JournalofHerbalMedicineandToxicology,vol.
4, pp. 141–144, 2010.
[16] R. Kagyung, P. R. Gajurel, P. Rethy, and B. Singh, “Ethno-
medicinal plants used for gastro-intestinal diseases by Adi
tribesofDehang-DebangBiosphereReserveinArunachalPra-
desh,”IndianJournalofTraditionalKnowledge,v ol.9,no .3,pp .
496–501, 2010.
[17] N. S. Jamir, Takatemjen, and Limasemba, “Traditional knowl-
edge of Lotha-Naga tribes in Wokha district, Nagaland,”
Indian Journal of Traditional Knowledge, vol. 9, no. 1, pp. 45–
48, 2010.
[18] M. Rahmatullah, M. S. Hossain, A. Hanif et al., “Ethnome-
dicinal applications of plants by the traditional healers of the
Marma tribe of Naikhongchhari, Bandarban district, Ban-
gladesh,” Advances in Natural and Applied Sciences, vol. 3, pp.
392–401, 2009.
[19] M. Rahmatullah, I. J. Mukti, A. K. M. Fahmidul Haque et al.,
“An ethnobotanical survey and pharmacological evaluation of
medicinal plants used by the Garo tribal community living in
Netrakona district, Bangladesh,” Advances in Natural and Ap-
plied Sciences, vol. 3, pp. 402–418, 2009.
[20] M. Rahmatullah, R. Jahan, M. S. Hossan et al., “A comparative
analysis of medicinal plants used by three tribes of Chittagong
hill tracts region, Bangladesh to treat leukorrhea,” Advances in
Natural and Applied Sciences, vol. 4, no. 2, pp. 148–152, 2010.
[21] M. Zakaria and M. A. Mohd, Traditional Malay Medicinal
Plants, Fajar Bakti Sdn. Bhd., Kuala Lumpur, Malaysia, 1994.
[22] D. Susanti, H. M. Sirat, F. Ahmad, R. M. Ali, N. Aimi, and
M. Kitajima, “Antioxidant and cytotoxic ﬂavonoids from the
ﬂowers of Melastoma malabathricum L,” Food Chemistry, vol.
103, no. 3, pp. 710–716, 2007.
[23] S. S. Koay, Establishment of cell suspension culture of Melastoma
malabathricum L. for the production of anthocyanin,P h . D .t h e -
sis, Universiti Sains Malaysia, Pulau Pinang, Malaysia, 2008.
[24] I. H. Burkill, A Dictionary of Economic Products of Malay
Peninsular, Ministry of Agriculture and Cooperatives, Kuala
Lumpur, Malaysia, 1966.
[ 2 5 ]I .B .J a g a n a t ha n dL .T .N g ,Herbs: The Green Pharmacy of
Malaysia, Vinpress Sdn. Bhd., Kuala Lumpur, Malaysia, 2000.
[26] D.BegumandS.C.Nath,“Ethnobotanicalreviewofmedicinal
plants used for skin diseases and related problems in North-
eastern India,” Journal of Herbs, Spices and Medicinal Plants,
vol. 7, no. 3, pp. 55–93, 2000.
[27] S. Bharadwaj and S. K. Gakhar, “Ethnomedicinal plants used
by tribals of Mizorum to use cuts and wounds,” Indian Journal
of Traditional Knowledge, vol. 4, pp. 75–80, 2005.Evidence-Based Complementary and Alternative Medicine 47
[28] T. W. Hugh Tan and C. K. Yeo, The Potential of Native Woody
Plants for Enhancing the Urban Waterways and Waterbodies
Environment in Singapore,R a ﬄes Museum of Biodiversity
Research and Singapore-Delft Water Alliance, National Uni-
versity Singapore, Singapore, 2009.
[29] A. Latiﬀ and A. H. Zakri, “Protection of Traditional Knowl-
edge, Innovations and Practices: The Malaysian Experience,”
in the UNCTAD Expert Meeting on Systems and National Ex-
periences for Protecting Traditional Knowledge, Innovations and
Practices, Geneva, Switzerland, October-November 2000.
[30] Z. A. Zakaria, M. N. R. N. S. Raden, G. Hanan Kumar et al.,
“Antinociceptive, anti-inﬂammatory and antipyretic proper-
tiesofMelastomamalabathricumleavesaqueousextractinex-
perimentalanimals,”CanadianJournalofPhysiologyandPhar-
macology, vol. 84, no. 12, pp. 1291–1299, 2006.
[31] A. L. Sajem and K. Gosai, “Traditional use of medicinal plants
by the Jaintia tribes in North Cachar Hills district of Assam,
northeast India,” Journal of Ethnobiology and Ethnomedicine,
vol. 2, article no. 33, 2006.
[32] F. Loh´ ezic-Le D´ ev´ ehat, A. Bakhtiar, C. B´ ezivin, M. Amoros,
andJ.Boustie,“AntiviralandcytotoxicactivitiesofsomeIndo-
nesian plants,” Fitoterapia, vol. 73, no. 5, pp. 400–405, 2002.
[33] K. W. Lin, “Ethnobotanical study of medicinal plants used by
the Jah Hut peoples in Malaysia,” Indian Journal of Medical
Sciences, vol. 59, no. 4, pp. 156–161, 2005.
[34] S. K. Jain and R. A. De Filipps, Medicinal Plants of India,
Reference Publication Inc., Algonac, Mich, USA, 1991.
[35] S. Mohandoss and P. Ravindran, “Flavonoids from Melastoma
melabathricum,” Fitoterapia, vol. 64, no. 3, pp. 277–278, 1993.
[36] L. M. Perry, Medicinal Plants of East and Southeast Asia,H a r -
vard University, Cambridge, Mass, USA, 1980.
[37] S. Elliott and J. Brimacombe, “The medicinal plants of Gun-
ung Leuser National Park, Indonesia,” Journal of Ethnophar-
macology, vol. 19, no. 3, pp. 285–317, 1987.
[38] H. C. Ong and M. Nordiana, “Malay ethno-medico botany in
Machang, Kelantan, Malaysia,” Fitoterapia,v o l .7 0 ,n o .5 ,p p .
502–513, 1999.
[39] H. C. Ong and J. Norzalina, “Malay herbal medicine in Gem-
encheh, Negri Sembilan, Malaysia,” Fitoterapia,v o l .7 0 ,n o .1 ,
pp. 10–14, 1999.
[40] K. Roosita, C. M. Kusharto, M. Sekiyama, Y. Fachrurozi, and
R. Ohtsuka, “Medicinal plants used by the villagers of a Sun-
danese community in West Java, Indonesia,” Journal of Ethno-
pharmacology, vol. 115, no. 1, pp. 72–81, 2008.
[41] J. B. Lowry, “The distribution and potential taxonomic value
of alkylated ellagic acids,” Phytochemistry, vol. 7, no. 10, pp.
1803–1813, 1968.
[42] J.B.Lowry,“Anthocyanins oftheMelastomataceae, Myrtaceae
and some allied families,” Phytochemistry,v o l .1 5 ,n o .4 ,p p .
513–516, 1976.
[ 4 3 ]M .M a n z o o r - I - K h u d a ,S .A .C h o w d h u r y ,T .R e z a ,a n dA .K .
Chowdhury, “Chemical Investigation on Melastoma Mala-
bathricum. Part 1: Isolation of Melastomic Acid and Beta-
sitosterol from the Roots,” Journal of the Bangladesh Academy
of Sciences, vol. 5, pp. 55–59, 1981.
[44] B. Dinda and M. K. Saha, “Aliphatic compounds from Melas-
toma malabathricum,” Journal of the Indian Chemical Society,
vol. 63, pp. 764–766, 1986.
[45] B. Dinda and M. K. Saha, “Fatty acid sterols from Melastoma
malabathricum,” JournaloftheIndianChemicalSociety,vol.63,
pp. 144–145, 1986.
[46] K. K. Dass and J. J. Kotoky, “A new aliphatic constituent of
Melastoma malabathricum Linn.,” J o u r n a lo ft h eI n d i a nC h e m -
ical Society, vol. 65, pp. 385–386, 1988.
[47] B. Dinda and M. K. Saha, “A ﬂavonol-diglycoside from Mela-
stoma malabathricum,” Journal of the Indian Chemical Society,
vol. 65, pp. 209–211, 1988.
[48] T. Yoshida, F. Nakata, K. Hosotani, A. Nitta, and T. Okuda,
“Dimeric hydrolysable tannins from Melastoma malabath-
ricum,” Phtochemistry, vol. 31, pp. 2829–2833, 1992.
[49] T. Yoshida, F. Nakata, K. Hosotani, A. Nitta, and T. Okuda,
“Tannins and related polyphenols of melastomataceous
plants. V. Three new complex tannins from Melastoma mala-
bathricum L,” Chemical and Pharmaceutical Bulletin, vol. 40,
no. 7, pp. 1727–1732, 1992.
[50] N. Pongprom, C. Khanapan, and P. Tosert, “Chemical consti-
tuentsofMelastomamalabathricumLinn,”inthe29thCongress
on Science and Technology of Thailand, p. 130, Khon Kaen,
Thailand, October 2003.
[51] S. Nuresti, S. H. Baek, and A. Asari, “Chemical components of
Melastoma malabathricum,” ACGC Chemical Research Com-
munications, vol. 16, pp. 28–33, 2003.
[52] D. M. H. Ali, K. C. Wong, and L. P. Boey, Triterpenoids, Gly-
colipids and Flavonoids of Melastoma malabathricum: Isola-
tion, Spectrometric Characterization and Antibacterial Activity,
VDM, Saarbr¨ ucken, Germany, 2010.
[ 5 3 ] K .C .W o n g ,P .L .B o e y ,a n dD .M .H .A l i ,“ P h y t o c h e m i c a la n d
biological study of Melastoma malabathricum L., a local plant
used in traditional medicine,” MIDAS Bulletin, vol. 32, p. 8,
2004.
[54] D. M. H. Ali, K. C. Wong, and L. P. Boey, “Flavonoids from
the Flowers of Melastoma malabathricum,” Working Paper.
Universiti Sains Malaysia, March 2001, http://eprints.usm.my/
8175/1/Flavonoids from the ﬂowers of Melastoma malabat-
hricum (PPSKimia).pdf.
[55] I.Nazlina,S.Norha,A.W.NoorZarina,andI.B.Ahmad,“Cy-
totoxicity and antiviral activity of Melastoma malabathricum
extracts,” Malaysian Journal of Applied Biology, vol. 37, pp. 53–
55, 2008.
[56] D. Susanti, H. M. Sirat, F. Ahmad, and R. Mat Ali, “Bioactive
constituents from the leaves of Melastoma malabathricum L.,”
Jurnal Ilmiah Farmasi, vol. 5, pp. 1–8, 2008.
[57] M. Simanjuntak, Ekstraksi and fraksinasi komponen ekstrak
daun tumbuhan senduduk (Melsatoma malabathricum) serta
pengujian efek sediaan krim terhadap penyembuhan luka
bakar, M.S. thesis, Universitas Sumatera Utara, Sumatera, In-
donesia, 2008, http://repository.usu.ac.id/bitstream/1234567-
89/14472/1/09E01171.pdf.
[58] M. Faravani, The population biology of Straits Rhododendron
(Melastoma malabathricum L.), Ph.D. thesis, University of
Malaya, Kuala Lumpur, Malaysia, 2009.
[59] B.DindaandM.K.Saha,“FreeaminoacidsofMelastoma mal-
abathricum,” JournaloftheIndianChemicalSociety,vol.62,pp.
789–790, 1985.
[60] H. H. Yeoh, Y. C. Wee, and L. Watson, “Leaf protein contents
and amino acid patterns of dicotyledonous plants,” Bio-
chemical Systematics and Ecology, vol. 20, no. 7, pp. 657–663,
1992.
[61] J. A. J. Sunilson, K. Anandarajagopal, A. V. A. G. Kumari, and
S.Mohan,“AntidiarrhoealactivityofleavesofMelastomamal-
abathricum linn,” Indian Journal of Pharmaceutical Sciences,
vol. 71, no. 6, pp. 691–695, 2009.
[62] P. W. Grosvenor, A. Supriono, and D. O. Gray, “Medicinal
plants from Riau Province, Sumatra, Indonesia. Part 2: anti-
bacterial and antifungal activity,” Journal of Ethnopharmacol-
ogy, vol. 45, no. 2, pp. 97–111, 1995.48 Evidence-Based Complementary and Alternative Medicine
[63] C. Wiart, S. Mogana, S. Khalifah et al., “Antimicrobial screen-
ingofplantsusedfortraditionalmedicineinthestateofPerak,
Peninsular Malaysia,” Fitoterapia, vol. 75, no. 1, pp. 68–73,
2004.
[64] L. Johnny, U. K. Yusuf, and R. Nulit, “The eﬀect of herbal
plantextractsonthegrowthandsporulationofColletotrichum
gloeosporioides,” Journal of Applied Biosciences, vol. 34, pp.
2218–2224, 2010.
[65] S. Maji, P. Dandapat, D. Ojha et al., “In vitro antimicrobial
potentialities of diﬀerent solvent extracts of ethnomedicinal
plants against clinically isolated human pathogens,” Journal of
Phytology, vol. 2, pp. 57–64, 2010.
[66] J.A.J.Sunilson,J.James,J.Thomas,P.Jayaraj,R.Varatharajan,
and M. Muthappan, “Antibacterial and wound healing activi-
ties of Melastoma malabathricum Linn.,” African Journal of In-
fectious Disease, vol. 2, pp. 68–73, 2008.
[67] Y. Alen, S. Nakajima, T. Nitoda, N. Baba, H. Kanzaki, and
K. Kawazu, “Antinematodal activity of some tropical rainfor-
est plants against the pinewood nematode Bursaphelenchus
xylophilus,” Zeitschrift fur Naturforschung C, vol. 55, no. 3-4,
pp. 295–299, 2000.
[68] C. Manicam, J. O. Abdullah, E. R. Mohd Tohit, Z. Seman, C.
C. Sieo, and M. Hamid, “In vitro anticoagulant activities of
Melastoma malabathricum Linn. aqueous leaf extract: a pre-
liminary novel ﬁnding,” Journal of Medicinal Plants Research,
vol. 4, pp. 1464–1472, 2010.
[ 6 9 ]I .J a n t a n ,I .A .A .R a ﬁ ,a n dJ .J a l i l ,“ P l a t e l e t - a c t i v a t i n gf a c t o r
(PAF)receptor-bindingantagonistactivityofMalaysianmedi-
cinal plants,” Phytomedicine, vol. 12, no. 1-2, pp. 88–92, 2005.
[70] M. P. Mazura, D. Susanti, and M. A. Rasadah, “Anti-inﬂam-
matory action of components from Melastoma malabathri-
cum,” Pharmaceutical Biology, vol. 45, no. 5, pp. 372–375,
2007.
[71] F. Hussain, M. A. Abdulla, S. M. Noor, S. Ismail, and H.
M.Ali,“GastroprotectiveeﬀectsofMelastomamalabathricum
aqueous leaf extract against ethanol-induced gastric ulcer iin
rats,” American Journal of Biochemistry and Biotechnology, vol.
4, no. 4, pp. 438–441, 2008.
[72] N. Uawonggul, A. Chaveerach, S. Thammasirirak, T. Arkar-
avichien, C. Chuachan, and S. Daduang, “Screening of plants
acting against Heterometrus laoticus scorpion venom activity
onﬁbroblastcelllysis,”JournalofEthnopharmacology,vol.103,
no. 2, pp. 201–207, 2006.
[73] M. R. Sulaiman, M. N. Somchit, D. A. Israf, Z. Ahmad, and
S. Moin, “Antinociceptive eﬀect of Melastoma malabathricum
ethanolic extract in mice,” Fitoterapia,v o l .7 5 ,n o .7 - 8 ,p p .
667–672, 2004.
[74] S. A. Mitchell and M. H. Ahmad, “A review of medicinal plant
research at the University of the West Indies, Jamaica, 1948–
2001,” WestIndian MedicalJournal,vol.55,no.4,pp.243–269,
2006.
[75] W.J.Craig,“Phytochemicals:guardiansofourhealth,”Journal
of the American Dietetic Association, vol. 97, no. 10, pp. S199–
204, 1997.
[76] N. J. Yob, S. Mohd. Joﬀr y ,M .M .R .M e o r .M o h d .A ﬀandi, L.
K. Teh, M. Z. Salleh, and Z. A. Zakaria, “Zingiber zerumbet
(L.) Smith: a review of its ethnomedicinal, chemical and phar-
macological uses,” Evidence-Based Complimentary and Alter-
native Medicine, vol. 2011, Article ID 543216, 12 pages, 2011.
[77] USEPA, “Points for discussion in the selection of dose levels
for mammalian in vivo Tier 1 assays,” December 2010, http://
www.epa.gov/endo/pubs/edmvs/tier1doseselectionptsv2.pdf.
[78] B. N. Meyer, N. R. Ferrigni, and J. E. Putnam, “Brine shrimp:
a convenient general bioassay for active plant constituents,”
Planta Medica, vol. 45, no. 1, pp. 31–34, 1982.